Multisystem inflammatory syndrome associated with COVID19 in children and adolescents: calling for diagnosis

Ulloa-Gutiérrez R, Ivankovich-Escoto G, Yamazaki-Nakashimada MA.

Letter: online search trends suggest patient concerns around immunosuppression use in inflammatory bowel disease during COVID-19 in the United Kingdom

Quraishi MN, Segal JP, Cooney R, Kennedy NA, Ainley R, Sharma N, Bhala NB, Brookes MJ.

COVID-19 infection and its deadly cytokine storm in a young obese adult

Abbas S, Ahmad A, Lacasse A.

A Controllable Inflammatory Response and Temporary Abnormal Coagulation in Moderate Disease of COVID-19 in Wuhan, China

Liu Y, Zhang X, Qiao J, Gong R, You Q, Sun J, Liu W, Sun B.

A public health perspective of aging: do hyper-inflammatory syndromes such as COVID-19, SARS, ARDS, cytokine storm syndrome, and post-ICU syndrome accelerate short- and long-term inflammaging?

Bektas A, Schurman SH, Franceschi C, Ferrucci L.

Hypercoagulopathy and Adipose Tissue Exacerbated Inflammation May Explain Higher Mortality in COVID-19 Patients With Obesity

Pasquarelli-do-Nascimento G, Braz-de-Melo HA, Faria SS, Santos IO, Kobinger GP, Magalh√£es KG.

A Novel Strategy to Mitigate the Hyperinflammatory Response to COVID-19 by Targeting Leukotrienes

Funk CD, Ardakani A.

Cytokine storm release syndrome and the prospects for immunotherapy with COVID-19, part 4: The role of JAK inhibition

Calabrese LH, Lenfant T, Calabrese C.

Biosensing Cytokine IL-6: A Comparative Analysis of Natural and Synthetic Receptors

Alfinito E, Beccaria M, Ciccarese M.

Severe clinical spectrum with high mortality in pediatric patients with COVID-19 and multisystem inflammatory syndrome

Pereira MFB, Litvinov N, Farhat SCL, Eisencraft AP, Gibelli MABC, Carvalho WB, Fernandes VR, Fink TT, Framil JVS, Galleti KV, Fante AL, Fonseca MFM, Watanabe A, Paula CSY, Palandri GG, Leal GN, Diniz MFR, Pinho JRR, Silva CA, Marques HHS; Pediatric COVID HC-FMUSP Study Group, Rossi Junior A, Delgado AF, Andrade APM, Schvartsman C, Sabino EC, Rocha MC, Kanunfre KA, Okay TS, Carneiro-Sampaio MMS, Jorge PPD.

Low level laser therapy as a modality to attenuate cytokine storm at multiple levels, enhance recovery, and reduce the use of ventilators in COVID-19

Mokmeli S, Vetrici M.

Reverse takotsubo cardiomyopathy in fulminant COVID-19 associated with cytokine release syndrome and resolution following therapeutic plasma exchange: a case-report

Faqihi F, Alharthy A, Alshaya R, Papanikolaou J, Kutsogiannis DJ, Brindley PG, Karakitsos D.

Synthesis of N,N'-bis(1,5-dimethyl-2-phenyl-1,2-dihydro-3-oxopyrazol-4-yl) sebacamide that ameliorate osteoarthritis symptoms and improve bone marrow matrix structure and cartilage alterations induced by monoiodoacetate in the rat model: "Suggested potent anti-inflammatory agent against COVID-19

Refat MS, Hamza RZ, Adam A, Saad HA, Gobouri AA, Al-Salmi FA, Altalhi T, El-Megharbel SM.

Children at risk: multisystem inflammatory syndrome and COVID-19

Beroukhim RS, Friedman K.

Correction to: The Perfect Moral Storm: Diverse Ethical Considerations in the COVID-19 Pandemic

Xafis V, Schaefer GO, Labude MK, Zhu Y, Hsu LY.

Modeling COVID-19 with Human Pluripotent Stem Cell-Derived Cells Reveals Synergistic Effects of Anti-inflammatory Macrophages with ACE2 Inhibition Against SARS-CoV-2

Duan F, Guo L, Yang L, Han Y, Thakur A, Nilsson-Payant BE, Wang P, Zhang Z, Ma CY, Zhou X, Han T, Zhang T, Wang X, Xu D, Duan X, Xiang J, Tse HF, Liao C, Luo W, Huang FP, Chen YW, Evans T, Schwartz RE, tenOever B, Ho DD, Chen S, Lian Q, Chen HJ.

Complete Heart Block, Severe Ventricular Dysfunction, and Myocardial Inflammation in a Child With COVID-19 Infection

El-Assaad I, Hood-Pishchany MI, Kheir J, Mistry K, Dixit A, Halyabar O, Mah DY, Meyer-Macaulay C, Cheng H.

Electrical Storm in COVID-19

O'Brien C, Ning N, McAvoy J, Mitchell JE, Kalwani N, Wang P, Nguyen D, Reejhsinghani R, Rogers A, Lorenzo J.

Can tocilizumab calm the cytokine storm of COVID-19?

Schulert GS.

Effectiveness of corticoid pulses in patients with cytokine storm syndrome induced by SARS-CoV-2 infection

Callejas Rubio JL, Luna Del Castillo JD, de la Hera Fern√°ndez J, Guirao Arrabal E, Colmenero Ruiz M, Ortego Centeno N.

Any port in a storm: Cryptocurrency safe-havens during the COVID-19 pandemic

Corbet S, Hou YG, Hu Y, Larkin C, Oxley L.

Use of Immunosuppressants/Immunomodulators in Autoimmune/Inflammatory Dermatologic Diseases during COVID-19 Pandemic-General Recommendation Based on Available Evidence

De D, Pandhi D.

Anti-interleukin-6 monoclonal antibody for cytokine storm in COVID-19

Douedi S, Chaudhri M, Miskoff J.

The looming storm: Blood and cytokines in COVID-19

Kaur S, Bansal R, Kollimuttathuillam S, Gowda AM, Singh B, Mehta D, Maroules M.

SARS-CoV-2 in cardiac tissue of a child with COVID-19-related multisystem inflammatory syndrome

Dolhnikoff M, Ferreira Ferranti J, de Almeida Monteiro RA, Duarte-Neto AN, Soares Gomes-Gouvêa M, Viu Degaspare N, Figueiredo Delgado A, Montanari Fiorita C, Nunes Leal G, Rodrigues RM, Taverna Chaim K, Rebello Pinho JR, Carneiro-Sampaio M, Mauad T, Ferraz da Silva LF, Brunow de Carvalho W, Saldiva PHN, Garcia Caldini E.

Longitudinal correlation of biomarkers of cardiac injury, inflammation, and coagulation to outcome in hospitalized COVID-19 patients

Li C, Jiang J, Wang F, Zhou N, Veronese G, Moslehi JJ, Ammirati E, Wang DW.

A Novel Pediatric Multisystem Inflammatory Syndrome During the COVID-19 Pandemic

Del Greco G, Brady K, Clark B, Park H.

Epidemiology and the Impact of Therapies on the Outcome of COVID-19 in Patients With Inflammatory Bowel Disease

Papa A, Gasbarrini A, Tursi A.

Endoscopic Evaluation of Inflammatory Bowel Disease With High-Grade Dysplasia Should Not Be Delayed During the COVID-19 Pandemic: A Case Report

Raphael KL, Trindade AJ, Zimmerman HM, Sultan KS.

IL-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine release syndrome

Kang S, Tanaka T, Inoue H, Ono C, Hashimoto S, Kioi Y, Matsumoto H, Matsuura H, Matsubara T, Shimizu K, Ogura H, Matsuura Y, Kishimoto T.

Setting up a Virtual Calprotectin Clinic in Inflammatory Bowel Diseases: Literature Review and Nancy Experience

D'Amico F, Netter P, Baumann C, Veltin M, Zallot C, Aimone-Gastin I, Danese S, Peyrin-Biroulet L.

Melatonin's Impact on Antioxidative and Anti-Inflammatory Reprogramming in Homeostasis and Disease

Chitimus DM, Popescu MR, Voiculescu SE, Panaitescu AM, Pavel B, Zagrean L, Zagrean AM.

COVID-19 and Inflammatory Bowel Disease: Patient Knowledge and Perceptions in a Single Center Survey

Spagnuolo R, Larussa T, Iannelli C, Cosco C, Nisticò E, Manduci E, Bruno A, Boccuto L, Abenavoli L, Luzza F, Doldo P.

A combinational approach to restore cytokine balance and to inhibit virus growth may promote patient recovery in severe COVID-19 cases

Mahmud-Al-Rafat A, Muzammal Haque Asim M, Taylor-Robinson AW, Majumder A, Muktadir A, Muktadir H, Karim M, Khan I, Mainul Ahasan M, Morsaline Billah M.

Effects of a major deletion in the SARS-CoV-2 genome on the severity of infection and the inflammatory response: an observational cohort study

Young BE, Fong SW, Chan YH, Mak TM, Ang LW, Anderson DE, Lee CY, Amrun SN, Lee B, Goh YS, Su YCF, Wei WE, Kalimuddin S, Chai LYA, Pada S, Tan SY, Sun L, Parthasarathy P, Chen YYC, Barkham T, Lin RTP, Maurer-Stroh S, Leo YS, Wang LF, Renia L, Lee VJ, Smith GJD, Lye DC, Ng LFP.

Implications for the Care of Patients With COVID-19 and Inflammatory Myocardial Disease-Reply

Inciardi RM, Lupi L, Metra M.

Implications for the Care of Patients With COVID-19 and Inflammatory Myocardial Disease

Di Tano G, Iacovoni A, De Maria R.

Patterns of acute surgical inflammatory processes presentation of in the COVID-19 outbreak (PIACO Study): Surgery may be the best treatment option

Guadalajara H, Muñoz de Nova JL, Fernandez Gonzalez S, Yiasemidou M, Recarte Rico M, Juez LD, García Septiem J, Galindo Jara P, García Virosta M, Lobo Martínez E, Martín-Pérez E, García-Olmo D; PIACO Collaboration Group.

Radiation oncology in times of COVID-2019: A review article for those in the eye of the storm - An Indian perspective

Hinduja RH, George K, Barthwal M, Pareek V.

Extracorporeal cytokine adsorption as an alternative to pharmacological inhibition of IL-6 in COVID-19

Supady A, Duerschmied D, Bode C, Rieder M, Lother A.

Ruxolitinib in COVID-19 Hyperinflammation and Haematologic Malignancies

La Rosée F, La Rosée P.

COVID-19 and multisystem inflammatory syndrome in children and adolescents

Jiang L, Tang K, Levin M, Irfan O, Morris SK, Wilson K, Klein JD, Bhutta ZA.

Levels of the TNF-Related Cytokine LIGHT Increase in Hospitalized COVID-19 Patients with Cytokine Release Syndrome and ARDS

Perlin DS, Zafir-Lavie I, Roadcap L, Raines S, Ware CF, Neil GA.

Monocytopenia, monocyte morphological anomalies and hyperinflammation characterise severe COVID-19 in type 2 diabetes

Alzaid F, Julla JB, Diedisheim M, Potier C, Potier L, Velho G, Gaborit B, Manivet P, Germain S, Vidal-Trecan T, Roussel R, Riveline JP, Dalmas E, Venteclef N, Gautier JF.

Multiorgan inflammatory syndrome associated with SARS-CoV-2 in a child

Rojahn AE, Gammelsrud KW, Brunvand LI, Hanche-Olsen TP, Schistad O, Sæter CB, Haaland K.

Ensuring editorial continuity and quality of science during the COVID-19 storm: the ICM experience

Bein T, Vargiolu A; ICM Editorial Board.

Editorial Comment on "Imaging Findings in Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with COVID-19"

Flors Blasco L.

The Hyper-Inflammatory Response in Adults with Severe COVID-19 Pneumonia Differs from the Cytokine Storm of Hemophagocytic Syndrome

Brikman S, Bieber A, Dori G.

Obesity, inflammation and COVID-19

Beretta A.

"Stay home stay safe?" Systemic inflammation in subjects undergoing routine hematology tests during the lockdown period of COVID-19

Tona F, Plebani M, Gregori D, Carretta G, Lorenzoni G, Donato D, Iliceto S.

Oxytocin's Anti-inflammatory and Pro-immune functions in COVID-19: A Transcriptomic Signature Based Approach

Imami AS, O'Donovan SM, Creeden JF, Wu X, Eby H, McCullumsmith CB, Uvnäs-Moberg K, McCullumsmith RE, Andari E.

Considerations for the Treatment of Inflammatory Neuro-Ophthalmologic Disorders During the COVID-19 Pandemic

Martin Paez Y, Bennett JL, Subramanian PS, Pelak VS.

Cardiac manifestations in SARS-CoV-2-associated multisystem inflammatory syndrome in children: a comprehensive review and proposed clinical approach

Sperotto F, Friedman KG, Son MBF, VanderPluym CJ, Newburger JW, Dionne A.

Spotlight on Tocilizumab in the Treatment of CAR-T-Cell-Induced Cytokine Release Syndrome: Clinical Evidence to Date

Si S, Teachey DT.

[Evolving Consensus of International Uveitis Study Group, Intraocular Inflammation Society, and Foster Ocular Inflammation Society with Uveitis in the Time of COVID-19 Infection]

Zierhut M, de MDS, Gupta V, Pavesio C, Nguyen QD, Chee SP, Agarwal R.

Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study

Pablos JL, Galindo M, Carmona L, Lledó A, Retuerto M, Blanco R, Gonzalez-Gay MA, Martinez-Lopez D, Castrejón I, Alvaro-Gracia JM, Fernández Fernández D, Mera-Varela A, Manrique-Arija S, Mena Vázquez N, Fernandez-Nebro A; RIER Investigators Group; RIER investigators group.

Autoimmunity to ACE2 as a possible cause of tissue inflammation in Covid-19

Townsend A.

Mismatch between circulating cytokines and spontaneous cytokine production by leukocytes in hyperinflammatory COVID-19

Kahn R, Schmidt T, Golestani K, Mossberg A, Gullstrand B, Bengtsson AA, Kahn F.

Coronavirus disease 2019 (COVID-19) in autoimmune and inflammatory conditions: clinical characteristics of poor outcomes

Montero F, Martínez-Barrio J, Serrano-Benavente B, González T, Rivera J, Molina Collada J, Castrejón I, Álvaro-Gracia J.

Worldwide Management of Inflammatory Bowel Disease During the COVID-19 Pandemic: An International Survey

Bernstein CN, Ng SC, Banerjee R, Steinwurz F, Shen B, Carbonnel F, Hamid S, Sood A, Yamamoto-Furusho JK, Griffiths A, Benchimol EI, Travis S, Lopes S, Rubin DT, Kaplan GG, Armstrong D, Gearry R; IBD-Emerging Nations Consortium and the WGO IBD Task Force on COVID-19.

The DHODH Inhibitor PTC299 Arrests SARS-CoV-2 Replication and Suppresses Induction of Inflammatory Cytokines

Luban J, Sattler R, Mühlberger E, Graci JD, Cao L, Weetall M, Trotta C, Colacino JM, Bavari S, Strambio-De-Castillia C, Suder EL, Wang Y, Soloveva V, Cintron-Lue K, Naryshkin NA, Pykett M, Welch EM, O'Keefe K, Kong R, Goodwin E, Jacobson A, Paessler S, Peltz S.

Tocilizumab exerts anti-inflammatory activity in six critically ill COVID-19 patients: a retrospective analysis

Qian S, An J, Qi F, Ye L, Chen Q, Liu X, Xie L, Li G.

COVID-19: Underlying Adipokine Storm and Angiotensin 1-7 Umbrella

Méry G, Epaulard O, Borel AL, Toussaint B, Le Gouellec A.

The Consequences of Coronavirus-Induced Cytokine Storm Are Associated With Neurological Diseases, Which May Be Preventable

Isacson O.

Hyperinflammation and the utility of immunomodulatory medications in children with COVID-19

Tanner T, Wahezi DM.

High-dose intravenous vitamin C may help in cytokine storm in severe SARS-CoV-2 infection

de Melo AF, Homem-de-Mello M.

Vascular endothelial injury exacerbates coronavirus disease 2019: The role of endothelial glycocalyx protection

Okada H, Yoshida S, Hara A, Ogura S, Tomita H.

Multisystem inflammatory syndrome associated with COVID-19 in children in Pakistan

Sadiq M, Aziz OA, Kazmi U, Hyder N, Sarwar M, Sultana N, Bari A, Rashid J.

COVID-19-Associated Multisystem Inflammatory Syndrome in Children - United States, March-July 2020

Godfred-Cato S, Bryant B, Leung J, Oster ME, Conklin L, Abrams J, Roguski K, Wallace B, Prezzato E, Koumans EH, Lee EH, Geevarughese A, Lash MK, Reilly KH, Pulver WP, Thomas D, Feder KA, Hsu KK, Plipat N, Richardson G, Reid H, Lim S, Schmitz A, Pierce T, Hrapcak S, Datta D, Morris SB, Clarke K, Belay E; California MIS-C Response Team.

Three Cases of Pediatric Multisystem Inflammatory Syndrome Associated with COVID-19 Due to SARS-CoV-2

Heidemann SM, Tilford B, Bauerfeld C, Martin A, Garcia RU, Yagiela L, Sarnaik AP.

Analysis of inflammatory parameters and disease severity for 88 hospitalized COVID-19 patients in Wuhan, China

Xu X, Yu MQ, Shen Q, Wang LZ, Yan RD, Zhang MY, Liu JY, Qu YQ.

Anti-inflammatory Properties of Stingless Bee Honey May Reduce the Severity of Pulmonary Manifestations in COVID-19 Infections

Mustafa MZ, Shamsuddin SH, Sulaiman SA, Abdullah JM.

Multisystem Inflammatory Syndrome in Children With COVID-19 in Mumbai, India

Jain S, Sen S, Lakshmivenkateshiah S, Bobhate P, Venkatesh S, Udani S, Shobhavat L, Andankar P, Karande T, Kulkarni S.

Serum protein profiling reveals a landscape of inflammation and immune signaling in early-stage COVID-19 infection

Hou X, Zhang X, Wu X, Lu M, Wang D, Xu M, Wang H, Liang T, Dai J, Duan H, Xu Y, Yu X, Li YZ.

Pentoxifylline and Oxypurinol: Potential Drugs to Prevent the "Cytokine Release (Storm) Syndrome" Caused by SARS-CoV-2?

López-Iranzo FJ, López-Rodas AM, Franco L, López-Rodas G.

The Striking Similarities of Multisystem Inflammatory Syndrome in Children and a Myocarditis-like Syndrome in Adults: Overlapping Manifestations of COVID-19

Most ZM, Hendren N, Drazner MH, Perl TM.

Prior Routine Use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Important Outcomes in Hospitalised Patients with COVID-19

Bruce E, Barlow-Pay F, Short R, Vilches-Moraga A, Price A, McGovern A, Braude P, Stechman MJ, Moug S, McCarthy K, Hewitt J, Carter B, Myint PK.

COVID-19 severity associates with pulmonary redistribution of CD1c+ DC and inflammatory transitional and nonclassical monocytes

Sánchez-Cerrillo I, Landete P, Aldave B, Sánchez-Alonso S, Sánchez-Azofra A, Marcos-Jiménez A, Ávalos E, Alcaraz-Serna A, de Los Santos I, Mateu-Albero T, Esparcia L, López-Sanz C, Martínez-Fleta P, Gabrie L, Del Campo Guerola L, de la Fuente H, Calzada MJ, González-Álvaro I, Alfranca A, Sánchez-Madrid F, Muñoz-Calleja C, Soriano JB, Ancochea J, Martín-Gayo E.

Anti-inflammatory and antiviral roles of hydrogen sulfide: rationale for considering H(2) S-donors in COVID-19 therapy

Citi V, Martelli A, Brancaleone V, Brogi S, Gojon G, Montanaro R, Morales G, Testai L, Calderone V.

A child with a severe multisystem inflammatory syndrome following an asymptomatic COVID-19 infection: A novel management for a new disease?

Giannattasio A, Maglione M, Zenzeri L, Mauro A, Di Mita O, Iodice RM, Tipo V.

Multi-System Inflammatory Syndrome in a Child Mimicking Kawasaki Disease

Gupta A, Gill A, Sharma M, Garg M.

Managing Hyperglycemia in the COVID-19 Inflammatory Storm

Gianchandani R, Esfandiari NH, Ang L, Iyengar J, Knotts S, Choksi P, Pop-Busui R.

Vascular inflammation and endothelial injury in SARS-CoV-2 infection: The overlooked regulatory cascades implicated by the ACE2 gene cluster

Shovlin CL, Vizcaychipi MP.

Systemic Inflammatory Response Syndrome Is a Major Contributor to COVID-19-Associated Coagulopathy: Insights From a Prospective, Single-Center Cohort Study

Masi P, Hékimian G, Lejeune M, Chommeloux J, Desnos C, Pineton De Chambrun M, Martin-Toutain I, Nieszkowska A, Lebreton G, Bréchot N, Schmidt M, Edouard Luyt C, Combes A, Frere C.

Paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS): providing resuscitative care

Kempsell-Smith M, Meenan S.

Clinical benefits of Tocilizumab in COVID-19-related cytokine release syndrome in a patient with end-stage kidney disease on haemodialysis in Australia

Stephen S, Park YA, Chrysostomou A.

The Impact of SARS-CoV-2 on Inflammatory Bowel Disease

Estevinho MM, Magro F.

Weather the Cytokine Storm: A Report of Successful Management of a Colon Cancer Survivor and a Critically Ill Patient with COVID-19

Khalid M, Dernaika T, Jacob L, Annamaraju P, Guddati AK.

Delayed severe cytokine storm and immune cell infiltration in SARS-CoV-2-infected aged Chinese rhesus macaques

Song TZ, Zheng HY, Han JB, Jin L, Yang X, Liu FL, Luo RH, Tian RR, Cai HR, Feng XL, Liu C, Li MH, Zheng YT.

Gender differences in the battle against COVID-19: impact of genetics, comorbidities, inflammation and lifestyle on differences in outcomes

Stoian AP, Toth PP, Kempler P, Rizzo M.

Immunity, inflammation and the vasculature in the COVID-19 era

Schutte AE, Harrison DG.

Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases

Freites Nuñez DD, Leon L, Mucientes A, Rodriguez-Rodriguez L, Font Urgelles J, Madrid García A, Colomer JI, Jover JA, Fernandez-Gutierrez B, Abasolo L.

The possible immunoregulatory and anti-inflammatory effects of selective serotonin reuptake inhibitors in coronavirus disease patients

Hamed MGM, Hagag RS.

Early Identification of COVID-19 Cytokine Storm and Treatment with Anakinra or Tocilizumab

Langer-Gould A, Smith JB, Gonzales EG, Castillo RD, Garza Figueroa J, Ramanathan A, Li BH, Gould MK.

Longitudinal Echocardiographic Assessment of Coronary Arteries and Left Ventricular Function Following Multisystem Inflammatory Syndrome in Children (MIS-C)

Jhaveri S, Ahluwalia N, Kaushik S, Trachtman R, Kowalsky S, Aydin S, Stern K.

Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with SARS-CoV-2: A Systematic Review

Abrams JY, Godfred-Cato SE, Oster ME, Chow EJ, Koumans EH, Bryant B, Leung JW, Belay ED.

Pediatric Multisystem Inflammatory Syndrome Temporally Associated With SARS-COV-2: Oral Manifestations and Implications

Riad A, Boccuzzi M, Sagiroglu D, Klugar M, Krsek M.

Inhibitory effects of Vitamin D on inflammation and IL-6 release. A further support for COVID-19 management?

Orr√π B, Szekeres-Bartho J, Bizzarri M, Spiga AM, Unfer V.

Coronavirus (Covid-19) sepsis: revisiting mitochondrial dysfunction in pathogenesis, aging, inflammation, and mortality

Shenoy S.

Clinical Trials for Inflammatory Bowel Disease: Global Guidance During the COVID-19 Pandemic

Reinisch W, Danese S, Peyrin-Biroulet L, Loftus EV.

Multimodality cardiac evaluation in children and young adults with multisystem inflammation associated with COVID-19

Theocharis P, Wong J, Pushparajah K, Mathur SK, Simpson JM, Pascall E, Cleary A, Stewart K, Adhvaryu K, Savis A, Kabir SR, Uy MP, Heard H, Peacock K, Miller O.

Subcutaneous tocilizumab treatment in patients with severe COVID-19-related cytokine release syndrome: An observational cohort study

Mastroianni A, Greco S, Apuzzo G, De Santis S, Oriolo C, Zanolini A, Chidichimo L, Vangeli V.

Preventing Mortality in COVID-19 Patients: Which Cytokine to Target in a Raging Storm?

Lu L, Zhang H, Zhan M, Jiang J, Yin H, Dauphars DJ, Li SY, Li Y, He YW.

Prominent Hypercoagulability Associated With Inflammatory State Among Cancer Patients With SARS-CoV-2 Infection

Xiong B, Liu T, Luo P, Wei Y, Zhou Y, Liu M, Zhang Y, Wang H, Zhang X, Wang X, Zhou F.

Decreased Naïve T-cell Production Leading to Cytokine Storm as Cause of Increased COVID-19 Severity with Comorbidities

Schwartz MD, Emerson SG, Punt J, Goff WD.

Dynamic Interleukin-6 Level Changes as a Prognostic Indicator in Patients With COVID-19

Liu Z, Li J, Chen D, Gao R, Zeng W, Chen S, Huang Y, Huang J, Long W, Li M, Guo L, Wang X, Wu X.

Single-cell analysis of two severe COVID-19 patients reveals a monocyte-associated and tocilizumab-responding cytokine storm

Guo C, Li B, Ma H, Wang X, Cai P, Yu Q, Zhu L, Jin L, Jiang C, Fang J, Liu Q, Zong D, Zhang W, Lu Y, Li K, Gao X, Fu B, Liu L, Ma X, Weng J, Wei H, Jin T, Lin J, Qu K.

Cardiac Involvment in SARS-CoV-2-Associated Inflammatory Syndromes

Picichè M.

Comment on Hu et al: The cytokine storm and COVID-19

Faqihi F, Alharthy A, Memish ZA, Karakitsos D.

Prominent coagulation disorder is closely related to inflammatory response and could be as a prognostic indicator for ICU patients with COVID-19

Liu Y, Gao W, Guo W, Guo Y, Shi M, Dong G, Ge Q, Zhu J, Lu J.

Multisystem Inflammatory Syndrome With Complete Kawasaki Disease Features Associated With SARS-CoV-2 Infection in a Young Adult. A Case Report

Cogan E, Foulon P, Cappeliez O, Dolle N, Vanfraechem G, De Backer D.

Prevention of Severe Coronavirus Disease 2019 Outcomes by Reducing Low-Grade Inflammation in High-Risk Categories

Ciornei RT.

Focus shifts to antibody cocktails for COVID-19 cytokine storm

Harrison C.

Atazanavir, alone or in combination with ritonavir, inhibits SARS-CoV-2 replication and pro-inflammatory cytokine production

Fintelman-Rodrigues N, Sacramento CQ, Ribeiro Lima C, Souza da Silva F, Ferreira AC, Mattos M, de Freitas CS, Cardoso Soares V, da Silva Gomes Dias S, Temerozo JR, Miranda MD, Matos AR, Bozza FA, Carels N, Alves CR, Siqueira MM, Bozza PT, Souza TML.

Correspondence on: 'Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort' by Pouletty et al

Pino R, Izurieta AC, Ríos-Barnés M, Ricart S, De Sevilla MF, Monfort L, Launes C, Cano I, Lecina L, Sánchez Manubens J, Mosquera JM, Jordan I, Sánchez de Toledo J, Monsonís M, Esteva C, Muñoz-Almagro C, Fumadó V, Fortuny C, Garcia Garcia JJ, Noguera-Julian A, Anton J; Kids Corona Project.

Response to: 'Correspondence on 'Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort' by Pouletty et al' by Pino et al

Ouldali N, Pouletty M, Lokmer J, Benzouid C, Beyler C, Deho A, Meinzer U, Faye A, Melki I; Great Paris Region (GPR) Kawa-COVID-19 consortium.

Acute respiratory distress syndrome from Covid-19: A perfect storm from free radicals? Proposal for a new treatment

Scigliano G, Scigliano GA.

Understanding Covid and the associated post-infectious hyper-inflammatory state (PIMS-TS) in children

Riphagen S.

Association of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with risk of COVID-19, inflammation level, severity, and death in patients with COVID-19: A rapid systematic review and meta-analysis

Liu X, Long C, Xiong Q, Chen C, Ma J, Su Y, Hong K.

[Recommendations of the German Society for Rheumatology for management of patients with inflammatory rheumatic diseases in the context of the SARS-CoV-2/COVID-19 pandemic - Update July 2020]

Schulze-Koops H, Iking-Konert C, Leipe J, Hoyer BF, Holle J, Moosig F, Aries P, Burmester G, Fiehn C, Krause A, Lorenz HM, Schneider M, Sewerin P, Voormann A, Wagner U, Krüger K, Specker C; Kommission Pharmakotherapie; Vorstand der Deutschen Gesellschaft für Rheumatologie.

Imaging Findings in Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with COVID

Blumfield E, Levin TL, Kurian J, Lee EY, Liszewski MC.

Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies

Tang Y, Liu J, Zhang D, Xu Z, Ji J, Wen C.

Cytokine Storm in COVID-19-Immunopathological Mechanisms, Clinical Considerations, and Therapeutic Approaches: The REPROGRAM Consortium Position Paper

Bhaskar S, Sinha A, Banach M, Mittoo S, Weissert R, Kass JS, Rajagopal S, Pai AR, Kutty S.

Cytokine storm release syndrome and the prospects for immunotherapy with COVID-19, part 3: The role of GM-CSF

Calabrese LH, Lenfant T, Calabrese C.

Treatment of patients with inflammatory rheumatic diseases with rituximab should be carefully considered during the SARS-CoV-2/COVID-19 pandemic. Response to: 'Persistence of rT-PCR-SARS-CoV-2 infection and delayed serological response, as a possible effect of rituximab according to the hypothes

Schulze-Koops H, Krueger K, Vallbracht IV, Hasseli R, Skapenko A.

Mouse model of SARS-CoV-2 reveals inflammatory role of type I interferon signaling

Israelow B, Song E, Mao T, Lu P, Meir A, Liu F, Alfajaro MM, Wei J, Dong H, Homer RJ, Ring A, Wilen CB, Iwasaki A.

Can Aldosterone increase Interleukin-6 levels in Covid-19 Pneumonia?

Campana P, Flocco V, Aruta F, Cacciatore F, Abete P.

Suppressed anti-inflammatory heat shock response in high-risk COVID-19 patients: lessons from basic research (inclusive bats), light on conceivable therapies

Heck TG, Ludwig MS, Frizzo MN, Rasia-Filho AA, Homem de Bittencourt PI.

A cytokine super cyclone in COVID-19 patients with risk factors: the therapeutic potential of BCG immunization

Johnson BS, Laloraya M.

Vascular occlusion by neutrophil extracellular traps in COVID-19

Leppkes M, Knopf J, Naschberger E, Lindemann A, Singh J, Herrmann I, Stürzl M, Staats L, Mahajan A, Schauer C, Kremer AN, Völkl S, Amann K, Evert K, Falkeis C, Wehrfritz A, Rieker RJ, Hartmann A, Kremer AE, Neurath MF, Muñoz LE, Schett G, Herrmann M.

IL-1 induces throboxane-A2 (TxA2) in COVID-19 causing inflammation and micro-thrombi: inhibitory effect of the IL-1 receptor antagonist (IL-1Ra)

Conti P, Caraffa A, Gallenga CE, Ross R, Kritas SK, Frydas I, Younes A, Di Emidio P, Ronconi G, Toniato E.

Targeting the cholinergic anti-inflammatory pathway with vagus nerve stimulation in patients with Covid-19?

Bonaz B, Sinniger V, Pellissier S.

Noninvasive monitoring of inflammatory bowel disease in the post COVID-19 era

Nardone OM, Rispo A, Castiglione F.

Attenuating hyperinflammation in COVID-19: A change in paradigm?

Molnar Z, Bakker J.

COVID-19-Associated Multisystem Inflammatory Syndrome in Children Presenting as Acute Pancreatitis

Stevens JP, Brownell JN, Freeman AJ, Bashaw H.

Adding Inflammation to the Perfect Cytokine Storm: Concerns Related to Extracorporeal Membrane Oxygenation for COVID-19 Patients

Angouras DC, Kollias VD, Dougenis D.

COVID-19 associated coagulopathy and inflammatory response: what do we know already and what are the knowledge gaps?

Görlinger K, Dirkmann D, Gandhi A, Simioni P.

Anxiety and depression in COVID-19 survivors: role of inflammatory and clinical predictors

Gennaro Mazza M, De Lorenzo R, Conte C, Poletti S, Vai B, Bollettini I, Maria Teresa Melloni E, Furlan R, Ciceri F, Rovere-Querini P, Benedetti F.

Impact of COVID-19 outbreak on the care of patients with inflammatory bowel disease: a comparison before and after the outbreak in South China

Zhang YF, Qiu Y, He JS, Tan JY, Li XZ, Zhu LR, Chen Y, Liu ZJ, Iacucci M, Chen BL, He Y, Ben-Horin S, Shen B, Zeng ZR, Ghosh S, Chen MH, Mao R.

Inflammatory Bowel Disease Management in a Major Referral Center During COVID-19 Pandemic

Garrido I, Lopes S, Macedo G.

IgGs drive COVID-19 myeloid hyperinflammation

Park MD.

Antiviral and Anti-Inflammatory Properties of Ivermectin and Its Potential Use in Covid-19

Portmann-Baracco A, Bryce-Alberti M, Accinelli RA.

Antecedent Immunosuppressive Therapy for Immune-Mediated Inflammatory Diseases in the Setting of a COVID-19 Outbreak

Veenstra J, Buechler CR, Robinson G, Chapman S, Adelman M, Tisack A, Dimitrion P, Todter E, Kohen L, Lim HW.

The role of cytokine profile and lymphocyte subsets in the severity of coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis

Akbari H, Tabrizi R, Lankarani KB, Aria H, Vakili S, Asadian F, Noroozi S, Keshavarz P, Faramarz S.

Anti-Inflammatory Properties of Drugs Used to Control COVID-19 and their Effects on the Renin-Angiotensin System and Angiotensin-Converting Enzyme-2

Gilzad-Kohan H, Jamali F.

Update on the COVID-19-associated inflammatory syndrome in children and adolescents; paediatric inflammatory multisystem syndrome-temporally associated with SARS-CoV-2

Singh-Grewal D, Lucas R, McCarthy K, Cheng AC, Wood N, Ostring G, Britton P, Crawford N, Burgner D.

The vascular nature of COVID-19

Oudkerk M, Kuijpers D, Oudkerk SF, van Beek EJ.

Papillophlebitis in a COVID-19 patient: Inflammation and hypercoagulable state

Insausti-García A, Reche-Sainz JA, Ruiz-Arranz C, López Vázquez Á, Ferro-Osuna M.

Impact of the COVID-19 Pandemic on Chronic Inflammatory Dermatoses: Mixed Messages Regarding the Dermatologist's Point of View and the Patient's Concerns

Fougerousse AC, Maccari F, Reguiai Z, Begon E, Pallure V, Taïeb C, Girard C, Mery-Bossard L.

The Effect of the COVID-19 Pandemic on the Medical Mode of Patients With Inflammatory Bowel Disease in China

Tian WN, Huang YH, Dai C.

Presenting features of COVID-19 in older people: relationships with frailty, inflammation and mortality

Knopp P, Miles A, Webb TE, Mcloughlin BC, Mannan I, Raja N, Wan B, Davis D.

High Inflammatory Burden: A Potential Cause of Myocardial Injury in Critically Ill Patients With COVID-19

Song Y, Gao P, Ran T, Qian H, Guo F, Chang L, Wu W, Zhang S.

Complement Inhibition in Coronavirus Disease (COVID)-19: A Neglected Therapeutic Option

Stahel PF, Barnum SR.

Impact of COVID-19 on diagnosis and management of paediatric inflammatory bowel disease during lockdown: a UK nationwide study

Ashton JJ, Kammermeier J, Spray C, Russell RK, Hansen R, Howarth LJ, Torrente F, Deb P, Renji E, Muhammed R, Paul T, Kiparissi F, Epstein J, Lawson M, Hope B, Zamvar V, Narula P, Kadir A, Devadason D, Bhavsar H, Beattie RM.

COVID-19 and Involvement of the Corpus Callosum: Potential Effect of the Cytokine Storm?

Rasmussen C, Niculescu I, Patel S, Krishnan A.

Correspondence on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry' by Gianfrancesco et al. Compassionate use of tocilizumab in severe COVID-19 with hyperinflammation pr

Khan A, Cole A, Bhadauria N, El-Hassan M, Abdulla D, Axon T, Fattah Z, Manson JJ, Moreno-Cuesta J, Mukerjee D.

Multisystem inflammatory syndrome in children and COVID-19 are distinct presentations of SARS-CoV-2

Diorio C, Henrickson SE, Vella LA, McNerney KO, Chase JM, Burudpakdee C, Lee JH, Jasen C, Balamuth F, Barrett DM, Banwell B, Bernt KM, Blatz AM, Chiotos K, Fisher BT, Fitzgerald JC, Gerber JS, Gollomp K, Gray C, Grupp SA, Harris RM, Kilbaugh TJ, Odom John AR, Lambert MP, Liebling EJ, Paessler M, Petrosa W, Phillips CA, Reilly AF, Romberg N, Seif AE, Sesok-Pizzini D, Sullivan K, Vardaro J, Behrens EM, Teachey DT, Bassiri H.

Is multisystem inflammatory syndrome in children on the Kawasaki syndrome spectrum?

Yeung RS, Ferguson PJ.

Association between cytokine profiles and lung injury in COVID-19 pneumonia

Chen LD, Zhang ZY, Wei XJ, Cai YQ, Yao WZ, Wang MH, Huang QF, Zhang XB.

Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis

Carvelli J, Demaria O, Vély F, Batista L, Benmansour NC, Fares J, Carpentier S, Thibult ML, Morel A, Remark R, André P, Represa A, Piperoglou C; Explore COVID-19 IPH group, Cordier PY, Le Dault E, Guervilly C, Simeone P, Gainnier M, Morel Y, Ebbo M, Schleinitz N, Vivier E; Explore COVID-19 Marseille Immunopole group.

JAK/STAT Pathway Inhibition May Be a Promising Therapy for COVID-19-Related Hyperinflammation in Hematologic Patients

Rojas P, Sarmiento M.

Cardiac Endotheliitis and Multisystem Inflammatory Syndrome After COVID-19

Fox SE, Lameira FS, Rinker EB, Vander Heide RS.

The ACE2-deficient mouse: A model for a cytokine storm-driven inflammation

Wang J, Kaplan N, Wysocki J, Yang W, Lu K, Peng H, Batlle D, Lavker RM.

Synergy between cytokines and risk factors in the cytokine storm of Covid-19: protection from the chronic use of cytokine inhibitors?

Miossec P.

COVID-19 in Patients with Inflammatory Arthritis: A Prospective Study on the Effects of Comorbidities and DMARDs on Clinical Outcomes

Haberman RH, Castillo R, Chen A, Yan D, Ramirez D, Sekar V, Lesser R, Solomon G, Niemann AL, Blank RB, Izmirly P, Webster DE, Ogdie A, Troxel AB, Adhikari S, Scher JU; NYU WARCOV Investigators.

Neuroinvasion, neurotropic, and neuroinflammatory events of SARS-CoV-2: understanding the neurological manifestations in COVID-19 patients

Yachou Y, El Idrissi A, Belapasov V, Ait Benali S.

COVID-19 Pandemic: Are Patients with Inflammatory Bowel Disease Really at Risk?

Hassan SA, Ezeh J.

COVID-19: disCOVering the role of complement system

Conigliaro P, Triggianese P, Perricone C, Chimenti MS, Perricone R.

Nonsteroidal anti-inflammatory drugs (NSAIDs) consideration by dermatologists during the COVID19 pandemic

Elsaie ML, Jafferany M, Jorgaqi E.

Inflammatory bowel disease management during the COVID-19 outbreak: The 10 do's and don'ts from the ECCO-COVID Taskforce

Magro F, Rahier JF, Abeu C, MacMahon E, Hart A, van der Woude CJ, Gordon H, Adamina M, Viget N, Vavricka S, Kucharzik T, Leone S, Siegmund B, Danese S, Peyrin-Biroulet L.

Immune Pathogenesis of COVID-19 Intoxication: Storm or Silence?

Kiselevskiy M, Shubina I, Chikileva I, Sitdikova S, Samoylenko I, Anisimova N, Kirgizov K, Suleimanova A, Gorbunova T, Varfolomeeva S.

Eosinophil-Derived Neurotoxin and Respiratory Tract Infection and Inflammation: Implications for COVID 19 Management

Dosanjh A.

[Steroid pulse -therapy in patients With coronAvirus Pneumonia (COVID-19), sYstemic inFlammation And Risk of vEnous thRombosis and thromboembolism (WAYFARER Study)]

Mareev VY, Orlova YA, Pavlikova EP, Matskeplishvili ST, Krasnova TN, Malahov PS, Samokhodskaya LM, Mershina EA, Sinitsyn VE, Mareev YV, Kalinkin AL, Begrambekova YL, Kamalov AA.

Case Report: Systemic Inflammatory Response and Fast Recovery in a Pediatric Patient With COVID-19

Klocperk A, Parackova Z, Dissou J, Malcova H, Pavlicek P, Vymazal T, Dolezalova P, Sediva A.

Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study

Ramiro S, Mostard RLM, Magro-Checa C, van Dongen CMP, Dormans T, Buijs J, Gronenschild M, de Kruif MD, van Haren EHJ, van Kraaij T, Leers MPG, Peeters R, Wong DR, Landewé RBM.

React, reset and restore: Adaptation of a large inflammatory bowel disease service during COVID-19 pandemic

Gonzalez HA, Myers S, Whitehead E, Pattinson A, Stamp K, Turnbull J, Fory R, Featherstone B, Wilkinson A, Lisle J, Haire G, Henderson E, Sebastian S.

Alpha-MSH targeted liposomal nanoparticle for imaging in Inflammatory Bowel Disease (IBD)

Medina TP, Damoah C, Benezra M, Will O, Kairemo K, Humbert J, Seben S, Medina OP.

COVID-19 in severe asthmatic patients during ongoing treatment with biologicals targeting type 2 inflammation: results from a multicenter Italian survey

Matucci A, Caminati M, Vivarelli V, Vianello A, Micheletto C, Menzella F, Crisafulli E, Passalacqua G, Bagnasco D, Lombardi C, Parronchi P, Crivellaro MA, Chieco-Bianchi F, Marchi MR, Guarnieri G, Cosmi L, Rossi O, Almerigogna F, Senna G, Vultaggio A.

Hypothesis: Pentoxifylline is a potential cytokine modulator therapeutic in COVID-19 patients

Hendry BM, Stafford N, Arnold AD, Sangwaiya A, Manglam V, Rosen SD, Arnold J.

Non-Steroidal Anti-Inflammatory Drugs and the Risk of Pneumonia Complications: A Systematic Review

Sodhi M, Khosrow-Khavar F, FitzGerald JM, Etminan M.

COVID-19 and Inflammatory Bowel Diseases: Risk Assessment, Shared Molecular Pathways, and Therapeutic Challenges

Popa IV, Diculescu M, Mihai C, Cijevschi-Prelipcean C, Burlacu A.

Overview: Systemic Inflammatory Response Derived From Lung Injury Caused by SARS-CoV-2 Infection Explains Severe Outcomes in COVID-19

Polidoro RB, Hagan RS, de Santis Santiago R, Schmidt NW.

Mouse Model of SARS-CoV-2 Reveals Inflammatory Role of Type I Interferon Signaling

Goldman-Israelow B, Song E, Mao T, Lu P, Meir A, Liu F, Alfajaro MM, Wei J, Dong H, Homer R, Ring A, Wilen C, Iwasaki A.

COVID-19 pneumonia: relationship between inflammation assessed by whole-body FDG PET/CT and short-term clinical outcome

Dietz M, Chironi G, Claessens YE, Farhad RL, Rouquette I, Serrano B, Nataf V, Hugonnet F, Paulmier B, Berthier F, Keita-Perse O, Giammarile F, Perrin C, Faraggi M; MONACOVID Group.

Inflammatory Markers in COVID-19

Bhandari S, Sharma S, Bhargava A, Keswani P, Sharma R, Shekhawat A.

Letter to the Editor: Lessons from COVID-19, ACE2 and intestinal inflammation - could a virus trigger chronic intestinal inflammation?

Hanrahan TP, Lubel JS, Garg M.

Multisystem inflammatory syndrome with particular cutaneous lesions related to COVID 19 in a young adult

Moghadam P, Blum L, Ahouach B, Radjou A, Lambert C, Scanvic A, Martres P, Decalf V, Bégon E, Bachmeyer C.

Multi-Inflammatory Syndrome in Children related to SARS-CoV-2 in Spain

Moraleda C, Serna-Pascual M, Soriano-Arandes A, Simó S, Epalza C, Santos M, Grasa C, Rodríguez M, Soto B, Gallego N, Ruiz Y, Urretavizcaya-Martínez M, Pareja M, Sanz-Santaeufemia FJ, Fumadó V, Lanaspa M, Jordan I, Prieto L, Belda S, Toral-Vázquez B, Rincón E, Gil-Villanueva N, Méndez-Echevarría A, Castillo-Serrano A, Rivière JG, Soler-Palacín P, Rojo P, Tagarro A.

Chronic inflammatory skin diseases and biologics: what to expect after COVID-19 pandemic?

Megna M, Fabbrocini G, Marasca C.

Lipoprotein(a) and Its Potential Association with Thrombosis and Inflammation in COVID-19: a Testable Hypothesis

Moriarty PM, Gorby LK, Stroes ES, Kastelein JP, Davidson M, Tsimikas S.

Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion

Simon D, Tascilar K, Krönke G, Kleyer A, Zaiss MM, Heppt F, Meder C, Atreya R, Klenske E, Dietrich P, Abdullah A, Kliem T, Corte G, Morf H, Leppkes M, Kremer AE, Ramming A, Pachowsky M, Schuch F, Ronneberger M, Kleinert S, Maier C, Hueber AJ, Manger K, Manger B, Berking C, Tenbusch M, Überla K, Sticherling M, Neurath MF, Schett G.

The Role of Glutathione in Protecting against the Severe Inflammatory Response Triggered by COVID-19

Silvagno F, Vernone A, Pescarmona GP.

Genetic Polymorphisms Complicate COVID-19 Therapy: Pivotal Role of HO-1 in Cytokine Storm

Fakhouri EW, Peterson SJ, Kothari J, Alex R, Shapiro JI, Abraham NG.

Hazards of the cytokine storm and cytokine-targeted therapy in COVID-19 patients: A Review

Quirch M, Lee J, Rehman S.

Therapeutic blockade of inflammation in severe COVID-19 infection with intravenous n-acetylcysteine

Ibrahim H, Perl A, Smith D, Lewis T, Kon Z, Goldenberg R, Yarta K, Staniloae C, Williams M.

Cytokine profile in plasma of severe COVID-19 does not differ from ARDS and sepsis

Wilson JG, Simpson LJ, Ferreira AM, Rustagi A, Roque JA, Asuni A, Ranganath T, Grant PM, Subramanian AK, Rosenberg-Hasson Y, Maecker H, Holmes S, Levitt JE, Blish C, Rogers AJ.

CXCL10 an important chemokine associated with cytokine storm in COVID-19 infected patients

Zhang N, Zhao YD, Wang XM.

American College of Rheumatology Clinical Guidance for Pediatric Patients with Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with SARS-CoV-2 and Hyperinflammation in COVID-19. Version 1

Henderson LA, Canna SW, Friedman KG, Gorelik M, Lapidus SK, Bassiri H, Behrens EM, Ferris A, Kernan KF, Schulert GS, Seo P, F Son MB, Tremoulet AH, Yeung RSM, Mudano AS, Turner AS, Karp DR, Mehta JJ.

Acute encephalopathy with elevated CSF inflammatory markers as the initial presentation of COVID-19

Farhadian S, Glick LR, Vogels CBF, Thomas J, Chiarella J, Casanovas-Massana A, Zhou J, Odio C, Vijayakumar P, Geng B, Fournier J, Bermejo S, Fauver JR, Alpert T, Wyllie AL, Turcotte C, Steinle M, Paczkowski P, Cruz CD, Wilen C, Ko AI, MacKay S, Grubaugh ND, Spudich S, Aoun Barakat L.

E-cigarette-Induced Pulmonary Inflammation and Dysregulated Repair are Mediated by nAChR α7 Receptor: Role of nAChR α7 in ACE2 Covid-19 receptor regulation

Wang Q, Sundar I, Li D, Lucas J, Muthumalage T, McDonough S, Rahman I.

Multisystem Inflammatory Syndrome in Children: Is There a Linkage to Kawasaki Disease?

Loke YH, Berul CI, Harahsheh AS.

Treatment of Cytokine Storm in COVID-19 Patients with Immunomodulatory Therapy

Yessayan L, Szamosfalvi B, Napolitano L, Singer B, Kurabayashi K, Song Y, Westover A, Humes D.

Distinct clinical and immunological features of SARS-COV-2-induced multisystem inflammatory syndrome in children

Lee PY, Day-Lewis M, Henderson LA, Friedman K, Lo J, Roberts JE, Lo MS, Platt CD, Chou J, Hoyt KJ, Baker AL, Banzon T, Chang MH, Cohen E, de Ferranti S, Dionne A, Habiballah S, Halyabar O, Hausmann JS, Hazen M, Janssen E, Meidan E, Nelson RW, Nguyen AA, Sundel RP, Dedeoglu F, Nigrovic PA, Newburger JW, Son MBF.

Non-steroidal anti-inflammatory drugs, prostaglandins and COVID-19

Robb CT, Goepp M, Rossi AG, Yao C.

Mild Cytokine Elevation, Moderate CD4(+)‚ÄâT Cell Response and Abundant Antibody Production in Children with COVID-19

Jia R, Wang X, Liu P, Liang X, Ge Y, Tian H, Chang H, Zhou H, Zeng M, Xu J.

Early IL-1 receptor blockade in severe inflammatory respiratory failure complicating COVID-19

Cauchois R, Koubi M, Delarbre D, Manet C, Carvelli J, Blasco VB, Jean R, Fouche L, Bornet C, Pauly V, Mazodier K, Pestre V, Jarrot PA, Dinarello CA, Kaplanski G.

Intensive immunosuppression reduces deaths in covid-19-associated cytokine storm syndrome, study finds

Mayor S.

¬øAre Superantigens the Cause of Cytokine Storm and viral sepsis in Severe COVID-19? Observations and hypothesis

Scaglioni V, Soriano ER.

Tocilizumab therapy in individuals with COVID-19 infection and hyperinflammatory state

McCarthy C, Savinelli S, Feeney ER, Butler MW, O'Broin C, Ryan S, O'Neill L, Murphy DJ, Gallagher CG, McKone EF, Waqas S, Cotter A, Doran P, Keane MP, Mallon PW.

Cytokine storm syndrome in coronavirus disease 2019: A narrative review

Gao YM, Xu G, Wang B, Liu BC.

Impact of Clinical Pharmacists in Inflammatory Bowel Disease Centers During the COVID-19 Pandemic

Bhat S, Farraye FA, Moss AC.

Emerging role of IL-6 and NLRP3 inflammasome as potential therapeutic targets to combat COVID-19: Role of lncRNAs in cytokine storm modulation

Paniri A, Akhavan-Niaki H.

The severe COVID-19: A sepsis induced by viral infection? and its immunomodulatory therapy

Lin HY.

Systemic inflammation with cardiac involvement in pediatric patients with evidence of COVID-19 in a community hospital in the Bronx, NY

Rogo T, Mathur K, Purswani M.

Severe immunosuppression and not a cytokine storm characterize COVID-19 infections

Remy KE, Mazer M, Striker DA, Ellebedy AH, Walton AH, Unsinger J, Blood TM, Mudd PA, Yi DJ, Mannion DA, Osborne DF, Martin RS, Anand NJ, Bosanquet JP, Blood J, Drewry AM, Caldwell CC, Turnbull IR, Brakenridge SC, Moldawer LL, Hotchkiss RS.

COVID-19 and the Heart and Vasculature: Novel Approaches to Reduce Virus-Induced Inflammation in Patients With Cardiovascular Disease

Kadosh BS, Garshick MS, Gaztanaga J, Moore KJ, Newman JD, Pillinger M, Ramasamy R, Reynolds HR, Shah B, Hochman J, Fishman GI, Katz SD.

Virus dissociated from inflammation in fatal COVID-19

Belabed M.

The Role of Interleukin-6 Inhibitors in the Treatment of COVID-19 Infections: A Case Series

Tadepalli S, Vanjarapu JMR, De Dona A, Cheriyath P, Nookala V.

Anti-inflammatory Properties of Stingless Bee Honey May Reduce the Severity of Pulmonary Manifestations in COVID-19 Infections?

Ch'ng ES, Tang TH.

COVID-19, Mast Cells, Cytokine Storm, Psychological Stress, and Neuroinflammation

Kempuraj D, Selvakumar GP, Ahmed ME, Raikwar SP, Thangavel R, Khan A, Zaheer SA, Iyer SS, Burton C, James D, Zaheer A.

Pediatric Inflammatory Multisystem Syndrome Temporally Associated With COVID-19

Sudhakar M, Jindal AK.

Hyperinflammatory Syndrome in Children Associated with COVID-19: Need for Awareness

Bhat CS, Gupta L, Balasubramanian S, Singh S, Ramanan AV.

Immuno-pathogenesis of nCOVID-19 and a possible host-directed therapy including anti-inflammatory and anti-viral prostaglandin (PG J(2)) for effective treatment and reduction in the death toll

Shahzad S, Willcox M.

Lipotoxicity and cytokine storm in severe acute pancreatitis and COVID-19

Hegyi P, Szakács Z, Sahin-Tóth M.

Targeting Cytokine Storm to Manage Patients with COVID-19: A Mini-Review

Roshanravan N, Seif F, Ostadrahimi A, Pouraghaei M, Ghaffari S.

COVID-19: what type of cytokine storm are we dealing with?

Monneret G, Benlyamani I, Gossez M, Martin JB, Martín-Fernandez M, Sesques P, Wallet F, Venet F.

Therapeutic plasma exchange in life-threatening COVID-19 and associated cytokine release syndrome

Faqihi F, Alharthy A, Karakitsos D.

Infliximab against severe COVID-19-induced cytokine storm syndrome with organ failure-a cautionary case series

Stallmach A, Kortgen A, Gonnert F, Coldewey SM, Reuken P, Bauer M.

The bio-mission of interleukin-6 in the pathogenesis of COVID-19: A brief look at potential therapeutic tactics

Abbasifard M, Khorramdelazad H.

Blocking inflammation on the way: Rationale for CXCR2 antagonists for the treatment of COVID-19

Koenig LM, Boehmer DFR, Metzger P, Schnurr M, Endres S, Rothenfusser S.

Cytokine Profile in an Adolescent With Pediatric Multisystem Inflammatory Syndrome Temporally Related to COVID-19

Buonsenso D, Di Sante G, Sali M; CURE COVID-19 Study Group.

Coronavirus 2019 Disease (COVID-19), Systemic Inflammation, and Cardiovascular Disease

Inciardi RM, Solomon SD, Ridker PM, Metra M.

COVID-19: the role of excessive cytokine release and potential ACE2 down-regulation in promoting hypercoagulable state associated with severe illness

Du F, Liu B, Zhang S.

Safety of Endoscopy in Patients With Inflammatory Bowel Disease During the COVID-19 Pandemic

Navaneethan U, Lourdusamy D, LehnerNoguera V, Shen B.

Mapping Systemic Inflammation and Antibody Responses in Multisystem Inflammatory Syndrome in Children (MIS-C)

Gruber C, Patel R, Trachman R, Lepow L, Amanat F, Krammer F, Wilson KM, Onel K, Geanon D, Tuballes K, Patel M, Mouskas K, Simons N, Barcessat V, Del Valle D, Udondem S, Kang G, Gangadharan S, Ofori-Amanfo G, Rahman A, Kim-Schulze S, Charney A, Gnjatic S, Gelb B, Merad M, Bogunovic D.

SARS-CoV-2 infection in the lungs of human ACE2 transgenic mice causes severe inflammation, immune cell infiltration, and compromised respiratory function

Winkler ES, Bailey AL, Kafai NM, Nair S, McCune BT, Yu J, Fox JM, Chen RE, Earnest JT, Keeler SP, Ritter JH, Kang LI, Dort S, Robichaud A, Head R, Holtzman MJ, Diamond MS.

"Small" Intestinal Immunopathology Plays a "Big" Role in Lethal Cytokine Release Syndrome, and Its Modulation by Interferon-γ, IL-17A, and a Janus Kinase Inhibitor

Kale SD, Mehrkens BN, Stegman MM, Kastelberg B, Carnes H, McNeill RJ, Rizzo A, Karyala SV, Coutermarsh-Ott S, Fretz JA, Sun Y, Koff JL, Rajagopalan G.

COVID-19 Sepsis and Microcirculation Dysfunction

Colantuoni A, Martini R, Caprari P, Ballestri M, Capecchi PL, Gnasso A, Lo Presti R, Marcoccia A, Rossi M, Caimi G.

Epidemiology and outcomes of novel coronavirus 2019 in patients with immune-mediated inflammatory diseases

Gianfrancesco M, Yazdany J, Robinson PC.

Staying afloat in the COVID-19 storm: GERIAtrics Fellows Learning Online And Together (GERI-A-FLOAT)

Duggan MC, Goroncy A, Christmas C, Chippendale R.

Insights into pediatric multi-system inflammatory syndrome and COVID-19

Bar-Ora D, Rael LT, Brody EN.

Single-cell analysis reveals bronchoalveolar epithelial dysfunction in COVID-19 patients

He J, Cai S, Feng H, Cai B, Lin L, Mai Y, Fan Y, Zhu A, Huang H, Shi J, Li D, Wei Y, Li Y, Zhao Y, Pan Y, Liu H, Mo X, He X, Cao S, Hu F, Zhao J, Wang J, Zhong N, Chen X, Deng X, Chen J.

Aging, Male Sex, Obesity, and Metabolic Inflammation Create the Perfect Storm for COVID-19

Mauvais-Jarvis F.

Rapid Radiological Worsening and Cytokine Storm Syndrome in COVID-19 Pneumonia

Ruch Y, Kaeuffer C, Guffroy A, Lefebvre N, Hansmann Y, Danion F.

Lessons learned from the mechanisms of posttraumatic inflammation extrapolated to the inflammatory response in COVID-19: a review

Teuben MPJ, Pfeifer R, Teuber H, De Boer LL, Halvachizadeh S, Shehu A, Pape HC.

Oral ulceration as presenting feature of paediatric inflammatory multisystem syndrome associated with COVID-19

Cant A, Bhujel N, Harrison M.

Cytokine adsorption in patients with severe COVID-19 pneumonia requiring extracorporeal membrane oxygenation

Rieder M, Wengenmayer T, Staudacher D, Duerschmied D, Supady A.

Tackling the cytokine storm in COVID-19, challenges, and hopes

Abdin SM, Elgendy SM, Alyammahi SK, Alhamad DW, Omar HA.

Hematolological Manifestations of COVID-19: From Cytopenia to Coagulopathy

Agbuduwe C, Basu S.

Management of childhood-onset autoinflammatory diseases during the COVID-19 pandemic

Haslak F, Yildiz M, Adrovic A, Sahin S, Koker O, Aliyeva A, Barut K, Kasapcopur O.

Prediction Model Based on the Combination of Cytokines and Lymphocyte Subsets for Prognosis of SARS-CoV-2 Infection

Luo Y, Mao L, Yuan X, Xue Y, Lin Q, Tang G, Song H, Wang F, Sun Z.

Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19

Juno JA, Tan HX, Lee WS, Reynaldi A, Kelly HG, Wragg K, Esterbauer R, Kent HE, Batten CJ, Mordant FL, Gherardin NA, Pymm P, Dietrich MH, Scott NE, Tham WH, Godfrey DI, Subbarao K, Davenport MP, Kent SJ, Wheatley AK.

Immune-mediated approaches against COVID-19

Florindo HF, Kleiner R, Vaskovich-Koubi D, Ac√∫rcio RC, Carreira B, Yeini E, Tiram G, Liubomirski Y, Satchi-Fainaro R.

Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients

Hadjadj J, Yatim N, Barnabei L, Corneau A, Boussier J, Smith N, Péré H, Charbit B, Bondet V, Chenevier-Gobeaux C, Breillat P, Carlier N, Gauzit R, Morbieu C, Pène F, Marin N, Roche N, Szwebel TA, Merkling SH, Treluyer JM, Veyer D, Mouthon L, Blanc C, Tharaux PL, Rozenberg F, Fischer A, Duffy D, Rieux-Laucat F, Kernéis S, Terrier B.

[Addendum to S3-Guidelines Crohn's disease and ulcerative colitis: Management of Patients with Inflammatory Bowel Disease in the COVID-19 Pandemic - open questions and answers]

Autoren; Collaborators:.

The role of a cytokine storm in severe COVID-19 disease in pregnancy

Wang X, Wang D, He S.

An adult with Kawasaki-like multisystem inflammatory syndrome associated with COVID-19

Shaigany S, Gnirke M, Guttmann A, Chong H, Meehan S, Raabe V, Louie E, Solitar B, Femia A.

Inflammatory olfactory neuropathy in two patients with COVID-19

Kirschenbaum D, Imbach LL, Ulrich S, Rushing EJ, Keller E, Reimann RR, Frauenknecht KBM, Lichtblau M, Witt M, Hummel T, Steiger P, Aguzzi A, Frontzek K.

Anti-inflammatory therapies for pericardial diseases in the COVID-19 pandemic: safety and potentiality

Imazio M, Brucato A, Lazaros G, Andreis A, Scarsi M, Klein A, De Ferrari GM, Adler Y.

Practical management of inflammatory bowel disease patients during the COVID-19 pandemic: expert commentary from the Gastroenterological Society of Australia Inflammatory Bowel Disease faculty

Aysha AA, Rentsch C, Prentice R, Johnson D, Bryant RV, Ward MG, Costello SP, Lewindon P, Ghaly S, Connor SJ, Begun J, Christensen B.

Lessons from dermatology about inflammatory responses in Covid-19

Criado PR, Pagliari C, Carneiro FRO, Quaresma JAS.

Letter: liver disease and COVID-19-not the perfect storm. Authors' reply"

Garrido I, Liberal R, Macedo G.

Social isolation due to the COVID-19 pandemic has led to worse outcomes in females with inflammatory arthritis

Maguire S, O'Shea F.

In the eye of the storm: the right ventricle in COVID-19

Park JF, Banerjee S, Umar S.

Targeting the Immune System for Pulmonary Inflammation and Cardiovascular Complications in COVID-19 Patients

Colafrancesco S, Scrivo R, Barbati C, Conti F, Priori R.

Cardiac Arrest Risk During Acute Infections: Systemic Inflammation Directly Prolongs QTc Interval via Cytokine-mediated Effects on Potassium Channel Expression

Lazzerini PE, Acampa M, Laghi-Pasini F, Bertolozzi I, Finizola F, Vanni F, Natale M, Bisogno S, Cevenini G, Cartocci A, Giabbani B, Migliacci N, D'Errico A, Dokollari A, Maccherini M, Boutjdir M, Capecchi PL.

Decrease of non-classical and intermediate monocyte subsets in severe acute SARS-CoV-2 infection

Gatti A, Radrizzani D, Viganò P, Mazzone A, Brando B.

COVID-19 in solid organ transplant recipients: dynamics of disease progression and inflammatory markers in ICU and non-ICU admitted patients

Roberts MB, Izzy S, Tahir Z, Al Jarrah A, Fishman JA, El Khoury J.

Frontal encephalopathy related to hyperinflammation in COVID-19

Cani I, Barone V, D'Angelo R, Pisani L, Allegri V, Spinardi L, Malpassi P, Fasano L, Rinaldi R, Fanti S, Cortelli P, Guarino M.

Management of Idiopathic CNS inflammatory diseases during the COVID-19 pandemic: Perspectives and strategies for continuity of care from a South East Asian Center with limited resources

Viswanathan S.

Prevention of endothelial dysfunction and thrombotic events in COVID-19 patients with familial hypercholesterolemia

Vuorio A, Kovanen PT.

Thromboinflammation in COVID-19 acute lung injury

Mitchell WB.

Immunomodulation for the management of corona virus disease (COVID-19)

Kiprov D, Conboy MJ, Conboy IM.

T cell renaissance in COVID-19

Garner L, Cifuentes L.

Reappearance of effector T cells is associated with recovery from COVID-19

Odak I, Barros-Martins J, Bošnjak B, Stahl K, David S, Wiesner O, Busch M, Hoeper MM, Pink I, Welte T, Cornberg M, Stoll M, Goudeva L, Blasczyk R, Ganser A, Prinz I, Förster R, Koenecke C, Schultze-Florey CR.

Harnessing adenosine A2A receptors as a strategy for suppressing the lung inflammation and thrombotic complications of COVID-19: Potential of pentoxifylline and dipyridamole

DiNicolantonio JJ, Barroso-Aranda J.

Eicosanoids: the Overlooked Storm in COVID-19?

Hammock BD, Wang W, Gilligan MM, Panigrahy D.

RV Infections in Asthmatics Increase ACE2 Expression and Cytokine Pathways Implicated in COVID-19

Chang EH, Willis AL, Romanoski CE, Cusanovich DA, Pouladi N, Li J, Lussier YA, Martinez FD.

More on Covid-19 in Immune-Mediated Inflammatory Diseases. Reply

Haberman RH, Adhikari S, Scher JU.

More on Covid-19 in Immune-Mediated Inflammatory Diseases

Briggs FBS, Gianfrancesco MA, George MF.

More on Covid-19 in Immune-Mediated Inflammatory Diseases

Peyrin-Biroulet L, Danese S.

More on Covid-19 in Immune-Mediated Inflammatory Diseases

Naldi L, Cazzaniga S.

COVID-19 and Headache Medicine: A Narrative Review of Non-Steroidal Anti-Inflammatory Drug (NSAID) and Corticosteroid Use

Arca KN, Smith JH, Chiang CC, Starling AJ, Robertson CE, Halker Singh RB, Schwedt TJ, Kissoon NR, Garza I, Rozen TD, Boes CJ, Whealy MA, VanderPluym JH.

Cytokine release syndrome and the prospects for immunotherapy with COVID-19. Part 2: The role of interleukin 1

Calabrese LH, Calabrese C.

Patients with COVID-19 present with low plasma citrulline concentrations that associate with systemic inflammation and gastrointestinal symptoms

Uzzan M, Soudan D, Peoch K, Weiss E, Corcos O, Treton X.

Adrenomedullin in COVID-19 induced endotheliitis

Wilson DC, Schefold JC, Baldirà J, Spinetti T, Saeed K, Elke G.

Effect of favipiravir and an anti-inflammatory strategy for COVID-19

Yamamura H, Matsuura H, Nakagawa J, Fukuoka H, Domi H, Chujoh S.

Protein Coding and Long Noncoding RNA (lncRNA) Transcriptional Landscape in SARS-CoV-2 Infected Bronchial Epithelial Cells Highlight a Role for Interferon and Inflammatory Response

Vishnubalaji R, Shaath H, Alajez NM.

Epithelial cilia is the first line of defence against Coronavirus; addressing the observed age-gradient in the COVID-19 infection

Lund Håheim L.

Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19

Zhang X, Zhang Y, Qiao W, Zhang J, Qi Z.

Correlation between cytokines and coagulation-related parameters in patients with coronavirus disease 2019 admitted to ICU

Zhang D, Zhou X, Yan S, Tian R, Su L, Ding X, Xiao M, Chen Y, Zhao H, Chen H, Zhang H, Li Z, Li Q, Xu Y, Yan X, Li Y, Zhang S.

Inflammasome Activation and Pyroptosis in Lymphopenic COVID-19 Liver Patients

Kroemer A, Khan K, Plassmeyer M, Alpan O, Haseeb MA, Gupta R, Fishbein TM.

The course of Covid 19 in Inflammatory Bowel Disease: protective role of TNF antagonists Response to: Corticosteroids, but not TNF Antagonists, are Associated with Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results from an International Registry

Cappello M, Busacca A, Guida L.

Effect of recombinant human granulocyte colony-stimulating factor on lymphocyte subsets in patients with COVID-19

Chen GB, Lin JT, Zhang Z, Liu L.

Inflammation, Immunity and Immunogenetics in COVID-19: A Narrative Review

Lingeswaran M, Goyal T, Ghosh R, Suri S, Mitra P, Misra S, Sharma P.

Immunological and inflammatory profiles in mild and severe cases of COVID-19

Song JW, Zhang C, Fan X, Meng FP, Xu Z, Xia P, Cao WJ, Yang T, Dai XP, Wang SY, Xu RN, Jiang TJ, Li WG, Zhang DW, Zhao P, Shi M, Agrati C, Ippolito G, Maeurer M, Zumla A, Wang FS, Zhang JY.

Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations

Marzolini C, Stader F, Stoeckle M, Franzeck F, Egli A, Bassetti S, Hollinger A, Osthoff M, Weisser M, Gebhard CE, Baettig V, Geenen J, Khanna N, Tschudin-Sutter S, Mueller D, Hirsch HH, Battegay M, Sendi P.

Higher level of Neutrophil-to-Lymphocyte is associated with severe COVID-19

Kong M, Zhang H, Cao X, Mao X, Lu Z.

How COVID-19 affects patients receiving anticytokine and JAK inhibitors in rheumatology and dermatology

Jessica Chang TY, Pope JE.

Global Storm of Stress-Related Psychopathological Symptoms: A Brief Overview on the Usefulness of Virtual Reality in Facing the Mental Health Impact of COVID-19

Imperatori C, Dakanalis A, Farina B, Pallavicini F, Colmegna F, Mantovani F, Clerici M.

Immunopathology of SARS-CoV-2 Infection: Immune Cells and Mediators, Prognostic Factors, and Immune-Therapeutic Implications

Allegra A, Di Gioacchino M, Tonacci A, Musolino C, Gangemi S.

Analysis of the intricate effects of polyunsaturated fatty acids and polyphenols on inflammatory pathways in health and disease

Margină D, Ungurianu A, Purdel C, Nitulescu GM, Tsoukalas D, Sarandi E, Thanasoula M, Burykina TI, Tekos F, Buha A, Nikitovic D, Kouretas D, Tsatsakis AM.

Hyperinflammatory shock related to COVID-19 in a patient presenting with multisystem inflammatory syndrome in children: First case from Iran

Bahrami A, Vafapour M, Moazzami B, Rezaei N.

Circulating Markers of Angiogenesis and Endotheliopathy in COVID-19

Meizlish M, Pine A, Goshua G, Chang CH, Zhang H, Bishai J, Bahel P, Patel A, Gbyli R, Kwan J, Price C, Dela Cruz C, Halene S, van Dijk D, Hwa J, Lee AI, Chun HJ.

SARS-CoV-2 Infection of Pluripotent Stem Cell-derived Human Lung Alveolar Type 2 Cells Elicits a Rapid Epithelial-Intrinsic Inflammatory Response

Huang J, Hume AJ, Abo KM, Werder RB, Villacorta-Martin C, Alysandratos KD, Beermann ML, Simone-Roach C, Olejnik J, Suder EL, Bullitt E, Hinds A, Sharma A, Bosmann M, Wang R, Hawkins F, Burks EJ, Saeed M, Wilson AA, Mühlberger E, Kotton DN.

Haematological manifestations, mechanisms of thrombosis and anti-coagulation in COVID-19 disease: A review

Kasinathan G, Sathar J.

The Potential Beneficial Effect of EPA and DHA Supplementation Managing Cytokine Storm in Coronavirus Disease

Szabó Z, Marosvölgyi T, Szabó É, Bai P, Figler M, Verzár Z.

Role of inflammatory markers in corona virus disease (COVID-19) patients: A review

Upadhyay J, Tiwari N, Ansari MN.

Treatment of Severe COVID-19 with Tocilizumab Mitigates Cytokine Storm and Averts Mechanical Ventilation During Acute Respiratory Distress: A Case Report and Literature Review

Farooqi F, Dhawan N, Morgan R, Dinh J, Nedd K, Yatzkan G.

Atherosclerosis as Pathogenetic Substrate for Sars-Cov2 Cytokine Storm

Vinciguerra M, Romiti S, Fattouch K, De Bellis A, Greco E.

Dynamic changes of peripheral blood lymphocytes subsets in adult patients with COVID-19

Deng Z, Zhang M, Zhu T, Liu Z, Liu Z, Xiang R, Zhang W, Xu Y.

Successful Treatment of Covid-19 Associated Cytokine Release Syndrome with Colchicine. A Case Report and Review of Literature

Mansouri N, Marjani M, Tabarsi P, von Garnier C, Mansouri D.

Covid-19 related IgA vasculitis

Allez M, Denis B, Bouaziz JD, Battistella M, Zagdanski AM, Bayart J, Lazaridou I, Gatey C, Pillebout E, Chaix Baudier ML, Delaugerre C, Molina JM, Le Goff J.

Anti-coagulation for COVID-19 treatment: both anti-thrombotic and anti-inflammatory?

Paar V, Wernly B, Zhou Z, Motloch LJ, Hoppe UC, Egle A, Lichtenauer M.

Serological tests confirm the low incidence of COVID-19 in chronic rheumatic inflammatory diseases treated with biological DMARD

Benucci M, Damiani A, Giannasi G, Li Gobbi F, Quartuccio L, Grossi V, Infantino M, Manfredi M.

COVID-19 associated Kawasaki-like multisystem inflammatory disease in an adult

Sokolovsky S, Soni P, Hoffman T, Kahn P, Scheers-Masters J.

Molecular chronicles of cytokine burst in patients with coronavirus disease 2019 (COVID-19) with cardiovascular diseases

Thankam FG, Agrawal DK.

Multi-System Inflammatory Syndrome in Children (MIS-C) Following SARS-CoV-2 Infection: Review of Clinical Presentation, Hypothetical Pathogenesis, and Proposed Management

Nakra NA, Blumberg DA, Herrera-Guerra A, Lakshminrusimha S.

Inflammatory Cell Infiltration of Adrenals in COVID-19

Zinserling VA, Semenova NY, Markov AG, Rybalchenko OV, Wang J, Rodionov RN, Bornstein SR.

Clinical course of COVID-19 in 41 patients with immune-mediated inflammatory diseases: experience from Humanitas Center, Milan

Allocca M, Guidelli GM, Borroni RG, Selmi C, Narcisi A, Danese S, Fiorino G.

Underestimation of co-infections in COVID-19 due to non-discriminatory use of antibiotics

Chang CY, Chan KG.

Elucidating the Pivotal Role of Immune Players in the Management of COVID-19: Focus on Mesenchymal Stem Cells and Inflammation

Richard SA, Kampo S, Sackey M, Hechavarria ME, Buunaaim ADB, Kuugbee ED, Anabah TW.

Regulatory T Cells for Treating Patients With COVID-19 and Acute Respiratory Distress Syndrome: Two Case Reports

Gladstone DE, Kim BS, Mooney K, Karaba AH, D'Alessio FR.

Questionnaire assessment helps the self-management of patients with inflammatory bowel disease during the outbreak of Coronavirus Disease 2019

Yu M, Ye Z, Chen Y, Qin T, Kou J, Tian D, Xiao F.

Potential role of IL-17 blocking agents in the treatment of severe COVID-19?

Bulat V, Situm M, Azdajic MD, Likic R.

Leucocyte Subsets Effectively Predict the Clinical Outcome of Patients With COVID-19 Pneumonia: A Retrospective Case-Control Study

Gan J, Li J, Li S, Yang C.

A case of cytokine hemofiltration and extracorporeal life support as treatment of coronavirus disease 2019 (COVID-19) respiratory failure

Al-Qudsi O, Whitson B, Bhatt A, Chucta S, Tripathi R.

THE COURAGE TO RETURN TO EVERYDAY LIFE AT THE TIME OF COVID-19: THE POINT OF VIEW OF INFLAMMATORY BOWEL DISEASE PATIENTS NEEDING ENDOSCOPY

Mocciaro F, Scimeca D, Di Mitri R.

Gastrointestinal involvements in children with COVID-related multisystem inflammatory syndrome

Chen TH, Kao WT, Tseng YH.

In the Same Storm but Different Boats

Brucker MC.

Early combination of Tocilizumab and Corticosteroids: An upgrade in anti-inflammatory therapy for severe COVID

Martínez-Urbistondo D, Costa Segovia R, Suárez Del Villar Carrero R, Risco Risco C, Villares Fernández P.

Multisystem Inflammatory Syndrome in Children in COVID-19 Pandemic

Shah SK, Munoz AC.

Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study

Della-Torre E, Campochiaro C, Cavalli G, De Luca G, Napolitano A, La Marca S, Boffini N, Da Prat V, Di Terlizzi G, Lanzillotta M, Rovere Querini P, Ruggeri A, Landoni G, Tresoldi M, Ciceri F, Zangrillo A, De Cobelli F, Dagna L; SARI-RAF Study Group; SARI-RAF Study Group members.

Demystifying pulmonary vascular complications in severe coronavirus disease-19 pneumonia (COVID-19) in the light of clinico-radiologic-pathologic correlation

Parry AH, Wani AH, Yaseen M, Dar MI.

Clostridiodes difficile in COVID-19 Patients, Detroit, Michigan, USA, March-April 2020

Lakkasani S, Chan KH, Shaaban HS.

Edaravone: a potential treatment for the COVID-19-induced inflammatory syndrome?

Reznik SE, Tiwari AK, Ashby CR Jr.

Clinical recurrences of COVID-19 symptoms after recovery: viral relapse, reinfection or inflammatory rebound?

Batisse D, Benech N, Botelho-Nevers E, Bouiller K, Collarino R, Conrad A, Gallay L, Goehringer F, Gousseff M, Joseph DC, Lemaignen A, Lescure FX, Levy B, Mahevas M, Penot P, Pozzetto B, Salmon D, Slama D, Vignier N, Wyplosz B.

Endothelial cells orchestrate COVID-19 coagulopathy

O'Sullivan JM, Gonagle DM, Ward SE, Preston RJS, O'Donnell JS.

Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study

Goshua G, Pine AB, Meizlish ML, Chang CH, Zhang H, Bahel P, Baluha A, Bar N, Bona RD, Burns AJ, Dela Cruz CS, Dumont A, Halene S, Hwa J, Koff J, Menninger H, Neparidze N, Price C, Siner JM, Tormey C, Rinder HM, Chun HJ, Lee AI.

Review of Societal Recommendations Regarding Management of Patients With Inflammatory Bowel Disease During the SARS-CoV-2 Pandemic

Grossberg LB, Pellish RS, Cheifetz AS, Feuerstein JD.

Coronavirus (COVID-19) Infection-Induced Chilblains: A Brisk Perieccrine Inflammatory Response

Wargo JJ, Weir NM, Shamma HN.

Statins as early therapy to mitigate COVID-19 (SARS-CoV-2)-associated ARDS and cytokine storm syndrome - time is of the essence

Teoh N, Farrell G.

Mapping the T cell response to COVID-19

Li J, Wang J, Kang AS, Sacitharan PK.

Potential of regulatory T cell-based therapies in the management of severe COVID-19

Stephen-Victor E, Das M, Karnam A, Pitard B, Gautier JF, Bayry J.

Intraluminal Carotid Artery Thrombus in COVID-19: Another Danger of Cytokine Storm?

Mohamud AY, Griffith B, Rehman M, Miller D, Chebl A, Patel SC, Howell B, Kole M, Marin H.

Mesenchymal stem cells in the fight against viruses: Face to face with the invisible enemy

Sleem A, Saleh F.

Naringenin, a flavanone with antiviral and anti-inflammatory effects: A promising treatment strategy against COVID-19

Tutunchi H, Naeini F, Ostadrahimi A, Hosseinzadeh-Attar MJ.

Low dose anti-inflammatory radiotherapy for the treatment of pneumonia by covid-19: A proposal for a multi-centric prospective trial

Algara M, Arenas M, Marin J, Vallverdu I, Fernandez-Letón P, Villar J, Fabrer G, Rubio C, Montero A.

Secondary Bacterial Infections in Critical Ill Patients With Coronavirus Disease 2019

Fu Y, Yang Q, Xu M, Kong H, Chen H, Fu Y, Yao Y, Zhou H, Zhou J.

The COVID-19 Cytokine Storm; What We Know So Far

Ragab D, Salah Eldin H, Taeimah M, Khattab R, Salem R.

Potential Treatments for COVID-19 Related Cytokine Storm - Beyond Corticosteroids

Miao Y, Fan L, Li JY.

Immune Response, Inflammation, and the Clinical Spectrum of COVID-19

García LF.

Is it Kawasaki shock syndrome, Kawasaki-like disease or pediatric inflammatory multisystem disease? The importance of semantic in the era of COVID-19 pandemic

Koné-Paut I, Cimaz R.

COVID-19 and TB co-infection - 'Finishing touch'' in perfect recipe to 'severity' or 'death'

Kumar DR, Bhattacharya DB, Meena DV, Soneja DM, Wig DN.

REPLY TO: Interleukin-17: a potential therapeutic target in COVID-19

Piaserico S, Meneguzzo A, Messina F.

Cytokine Storms: Understanding COVID-19

Mangalmurti N, Hunter CA.

Oropharyngeal candidiasis in hospitalized COVID-19 Patients from Iran: Species identification and antifungal susceptibility pattern

Salehi M, Ahmadikia K, Mahmoudi S, Kalantari S, Jamalimoghadam Siahkali S, Izadi A, Kord M, Dehghan Manshadi SA, Seifi A, Ghiasvand F, Khajavirad N, Ebrahimi S, Koohfar A, Boekhout T, Khodavaisy S.

Influenza-induced thrombocytopenia is dependent on the subtype and sialoglycan receptor and increases with virus pathogenicity

Jansen AJG, Spaan T, Low HZ, Di Iorio D, van den Brand J, Tieke M, Barendrecht A, Rohn K, van Amerongen G, Stittelaar K, Baumgärtner W, Osterhaus A, Kuiken T, Boons GJ, Huskens J, Boes M, Maas C, van der Vries E.

COVID-19 Severity Correlates with Weaker T Cell Immunity, Hypercytokinemia and Lung Epithelium Injury

Wang Z, Yang X, Zhou Y, Sun J, Liu X, Zhang J, Mei X, Zhong J, Zhao J, Ran P.

Peripheral lymphocyte subset alterations in COVID-19 patients

Chan SSW, Christopher D, Tan GB, Chong VCL, Fan BE, Lin CY, Ong KH.

COVID-19: a collision of complement, coagulation and inflammatory pathways

Chauhan AJ, Wiffen LJ, Brown TP.

Hypercytokinemia and Pathogen-Host Interaction in COVID-19

Badawi A.

Potential Role of Nrf2 Activators with Dual Antiviral and Anti-Inflammatory Properties in the Management of Viral Pneumonia

Lin CY, Yao CA.

COVID-19 treatment: Combining anti-inflammatory and antiviral therapeutics using a network-based approach

Cheng F, Rao S, Mehra R.

Cytokines and the still-baffling clinical biology of COVID-19

Mandell BF.

Letter to the editor on the outcomes in fracture patients infected with COVID-19

Rizkallah M, Melhem E, Sadeqi M, Meyblum J, Jouffroy P, Riouallon G.

Cytokine Storm in COVID19: A Neural Hypothesis

Ur A, Verma K.

Clinical and Psychological Impact of COVID-19 Infection in Adult Patients with Eosinophilic Gastrointestinal Disorders during the SARS-CoV-2 Outbreak

Savarino EV, Iovino P, Santonicola A, Ghisa M, Laserra G, Barberio B, Maniero D, Lorenzon G, Ciacci C, Savarino V, Zingone F.

COVID-19 Infection: Perioperative Implications: Reply

Greenland JR, Michelow MD, Wang L, London MJ.

COVID-19 Infection: Perioperative Implications: Comment

Mahajan C, Kapoor I, Prabhakar H.

Bacterial and fungal coinfection among hospitalised patients with COVID-19: A retrospective cohort study in a UK secondary care setting

Hughes S, Troise O, Donaldson H, Mughal N, Moore LS.

Targeting inflammation and cytokine storm in COVID-19

Huang Q, Wu X, Zheng X, Luo S, Xu S, Weng J.

Vitamin D and Inflammation: Potential Implications for Severity of Covid-19

Laird E, Rhodes J, Kenny RA.

Is a "Cytokine Storm" Relevant to COVID-19?

Sinha P, Matthay MA, Calfee CS.

Endothelial dysfunction in Coronavirus disease 2019 (COVID-19): Gender and age influences

Froldi G, Dorigo P.

Retinal outcomes of COVID-19: possible role of CD147 and cytokine storm in infected patients with diabetes mellitus

Raony Í, Saggioro de Figueiredo C.

The cytokine storm and COVID-19

Hu B, Huang S, Yin L.

Bilateral anterior uveitis as a part of a multisystem inflammatory syndrome secondary to COVID-19 infection

Bettach E, Zadok D, Weill Y, Brosh K, Hanhart J.

Clinical course and outcome of COVID-19 in patients with rheumatic diseases: are all biological disease-modifying antirheumatic drugs alike? Response to: 'Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab' by Schulze-Koops et al

Monti S, Montecucco C.

Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab

Schulze-Koops H, Krueger K, Vallbracht I, Hasseli R, Skapenko A.

Pneumococcal superinfection in COVID-19 patients: A series of 5 cases

Cucchiari D, Pericàs JM, Riera J, Gumucio R, Md EC, Nicolás D; Hospital Clínic 4H Team.

NewsCAP: Multisystem inflammatory syndrome in children appears to be related to COVID-19

Endothelial progenitor cells and mesenchymal stem cells to overcome vascular deterioration and cytokine storm in critical patients with COVID-19

Karaahmet F, Kocaman SA.

A Brewing Storm: The Neuropsychological Sequelae of Hyperinflammation due to COVID-19

Cothran TP, Kellman S, Singh S, Beck JS, Powell KJ, Bolton CJ, Tam JW.

Severe COVID-19 and Healthcare Associated Infections on the ICU: Time to Remember the Basics?

Sturdy A, Basarab M, Cotter M, Hager K, Shakespeare D, Shah N, Randall P, Spray D, Arnold A.

Zero COVID-19 infection in inflammatory bowel disease patients: Findings from National IBD Registries in Hong Kong and Taiwan

Mak JWY, Weng MT, Wei SC, Ng SC.

Attenuated early inflammatory response in solid organ recipients with COVID-19

Bösch F, Börner N, Kemmner S, Lampert C, Jacob S, Koliogiannis D, Stangl M, Michel S, Kneidinger N, Schneider C, Fischereder M, Irlbeck M, Denk G, Werner J, Angele MK, Guba MO.

The protective rather than prothrombotic fibrinogen in COVID-19 and other inflammatory states

Thachil J.

Auxiliary role of mesenchymal stem cells as regenerative medicine soldiers to attenuate inflammatory processes of severe acute respiratory infections caused by COVID-19

Parhizkar Roudsari P, Alavi-Moghadam S, Payab M, Sayahpour FA, Aghayan HR, Goodarzi P, Mohamadi-Jahani F, Larijani B, Arjmand B.

A Digital Protein Microarray for COVID-19 Cytokine Storm Monitoring

Song Y, Ye Y, Su SH, Stephens A, Cai T, Chung MT, Han M, Newstead MW, Frame D, Singer BH, Kurabayashi K.

Pulmonary toxicity and inflammatory response of e-cigarettes containing medium-chain triglyceride oil and vitamin E acetate: Implications in the pathogenesis of EVALI but independent of SARS-COV-2 COVID-19 related proteins

Muthumalage T, Lucas JH, Wang Q, Lamb T, McGraw MD, Rahman I.

Potential contribution of increased soluble IL-2R to lymphopenia in COVID-19 patients

Zhang Y, Wang X, Li X, Xi D, Mao R, Wu X, Cheng S, Sun X, Yi C, Ling Z, Ma L, Ning Q, Fang Y, Sun B, Wu D.

CytoResc - "CytoSorb" Rescue for critically ill patients undergoing the COVID-19 Cytokine Storm: A structured summary of a study protocol for a randomized controlled trial

Stockmann H, Keller T, Büttner S, Jörres A, Kindgen-Milles D, Kunz JV, Leebmann J, Spies C, Träger K, Treskatsch S, Uhrig A, Willam C, Enghard P, Slowinski T; CytoResc Trial Investigators.

Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment

Yeleswaram S, Smith P, Burn T, Covington M, Juvekar A, Li Y, Squier P, Langmuir P.

Comment on: "To consider varicella-like exanthem associated with COVID-19, virus varicella zoster and virus herpes simplex must be ruled out. Characterization of herpetic lesions in hospitalized COVID-19 patients."

Fernandez-Nieto D, Ortega-Quijano D, Suarez-Valle A, Burgos-Blasco P, Jimenez-Cauhe J, Fernandez-Guarino M.

Elective surgeries during COVID-19 storm: The best surgeon knows when not to operate

Atik O≈û.

Characterization of the Inflammatory Response to Severe COVID-19 Illness

McElvaney OJ, McEvoy N, McElvaney OF, Carroll TP, Murphy MP, Dunlea DM, Ní Choileáin O, Clarke J, O'Connor E, Hogan G, Ryan D, Sulaiman I, Gunaratnam C, Branagan P, O'Brien ME, Morgan RK, Costello RW, Hurley K, Walsh S, de Barra E, McNally C, McConkey S, Boland F, Galvin S, Kiernan F, O'Rourke J, Dwyer R, Power M, Geoghegan P, Larkin C, O'Leary RA, Freeman J, Gaffney A, Marsh B, Curley GF, McElvaney NG.

Multisystem Inflammatory Syndrome in Children (MIS-C) Related to COVID-19: A New York City Experience

Riollano-Cruz M, Akkoyun E, Briceno-Brito E, Kowalsky S, Posada R, Sordillo EM, Tosi M, Trachtman R, Paniz-Mondolfi A.

COVID-19 infection on IL-23 inhibition

Wang CJ, Truong AK.

Amelioration of COVID-19 related cytokine storm syndrome: Parallels to chimeric antigen receptor-T cell cytokine release syndrome

Hoiland RL, Stukas S, Cooper J, Thiara S, Chen LYC, Biggs CM, Hay K, Lee AYY, Shojania K, Abdulla A, Wellington CL, Sekhon MS.

Spectrum of Imaging Findings on Chest Radiographs, US, CT, and MRI Images in Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with COVID-19

Hameed S, Elbaaly H, Reid CEL, Santos RMF, Shivamurthy V, Wong J, Jogeesvaran KH.

Letter: intestinal inflammation, COVID-19 and gastrointestinal ACE2-exploring RAS inhibitors-authors' reply

Taxonera C, Sagastagoitia I, Alba C, Mañas N, Olivares D, Rey E.

Age-related decline of de novo T cell responsiveness as a cause of COVID-19 severity

Nicoli F, Solis-Soto MT, Paudel D, Marconi P, Gavioli R, Appay V, Caputo A.

Neurological manifestations of pediatric multi-system inflammatory syndrome potentially associated with COVID-19

Schupper AJ, Yaeger KA, Morgenstern PF.

Stopping Clinical Trials in Inflammatory Bowel Disease During the COVID-19 Pandemic is not a Responsible Act

Schreiber S, Dignass A, Rogge A, Rubin DT.

Immune-Inflammatory Parameters in COVID-19 Cases: A Systematic Review and Meta-Analysis

Feng X, Li S, Sun Q, Zhu J, Chen B, Xiong M, Cao G.

Neutrophils, Crucial, or Harmful Immune Cells Involved in Coronavirus Infection: A Bioinformatics Study

Hemmat N, Derakhshani A, Bannazadeh Baghi H, Silvestris N, Baradaran B, De Summa S.

Neutrophilia and NETopathy as Key Pathologic Drivers of Progressive Lung Impairment in Patients With COVID-19

Narasaraju T, Tang BM, Herrmann M, Muller S, Chow VTK, Radic M.

Repositioning Chromones for Early Anti-inflammatory Treatment of COVID-19

Sestili P, Stocchi V.

Targeting lymphocyte Kv1.3-channels to suppress cytokine storm in severe COVID-19: Can it be a novel therapeutic strategy?

Kazama I.

COVID-19 Hyperinflammation: What about Neutrophils?

Didangelos A.

Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19

Luo W, Li YX, Jiang LJ, Chen Q, Wang T, Ye DW.

A Case of Pediatric Multisystem Inflammatory Syndrome Temporally Associated with COVID-19 in South Dakota

Dasgupta K, Finch SE.

Hyperferritinemia in critically ill COVID-19 patients - Is ferritin the product of inflammation or a pathogenic mediator?

Gómez-Pastora J, Weigand M, Kim J, Wu X, Strayer J, Palmer AF, Zborowski M, Yazer M, Chalmers JJ.

SARS-CoV-2-reactive interferon-γ-producing CD8(+) T cells in patients hospitalized with Coronavirus Disease 2019

Giménez E, Albert E, Torres I, Remigia MJ, Alcaraz MJ, Galindo MJ, Blasco ML, Solano C, Forner MJ, Redón J, Signes-Costa J, Navarro D.

Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019: The GRECCO-19 Randomized Clinical Trial

Deftereos SG, Giannopoulos G, Vrachatis DA, Siasos GD, Giotaki SG, Gargalianos P, Metallidis S, Sianos G, Baltagiannis S, Panagopoulos P, Dolianitis K, Randou E, Syrigos K, Kotanidou A, Koulouris NG, Milionis H, Sipsas N, Gogos C, Tsoukalas G, Olympios CD, Tsagalou E, Migdalis I, Gerakari S, Angelidis C, Alexopoulos D, Davlouros P, Hahalis G, Kanonidis I, Katritsis D, Kolettis T, Manolis AS, Michalis L, Naka KK, Pyrgakis VN, Toutouzas KP, Triposkiadis F, Tsioufis K, Vavouranakis E, Martinèz-Dol

Systemic inflammatory response and thrombosis due to alterations in the gut microbiota in COVID-19

Mönkemüller K, Fry LC, Rickes S.

COVID-19. Immunothrombosis and the gastrointestinal tract

A Cienfuegos J, Almeida Vargas A, S√°nchez Justicia C.

From the American Epicenter: Coronavirus Disease 2019 in Patients with Inflammatory Bowel Disease in the New York City Metropolitan Area

Axelrad JE, Malter L, Hong S, Chang S, Bosworth B, Hudesman D.

Serology confirms SARS-CoV-2 infection in PCR-negative children presenting with Paediatric Inflammatory Multi-System Syndrome

Perez-Toledo M, Faustini SE, Jossi SE, Shields AM, Kanthimathinathan HK, Allen JD, Watanabe Y, Goodall M, Wraith DC, Veenith TV, Drayson MT, Jyothish D, Al-Abadi E, Chikermane A, Welch SB, Masilamani K, Hackett S, Crispin M, Scholefield BR, Cunningham AF, Richter AG.

Mouse model of SARS-CoV-2 reveals inflammatory role of type I interferon signaling

Israelow B, Song E, Mao T, Lu P, Meir A, Liu F, Alfajaro MM, Wei J, Dong H, Homer RJ, Ring A, Wilen CB, Iwasaki A.

DREAM-in-CDM Approach and Identification of a New Generation of Anti-inflammatory Drugs Targeting mPGES-1

Zhou S, Zhou Z, Ding K, Yuan Y, Loftin C, Zheng F, Zhan CG.

[Relationship between D-dimer concentration and inflammatory factors or organ function in patients with coronavirus disease 2019]

Xu Y, Qian Y, Gu Q, Tang J.

Re-analysis of SARS-CoV-2-infected host cell proteomics time-course data by impact pathway analysis and network analysis: a potential link with inflammatory response

Bock JO, Ortea I.

Targeting innate immunity by blocking CD14: Novel approach to control inflammation and organ dysfunction in COVID-19 illness

Martin TR, Wurfel MM, Zanoni I, Ulevitch R.

Alveolar macrophage dysfunction and cytokine storm in the pathogenesis of two severe COVID-19 patients

Wang C, Xie J, Zhao L, Fei X, Zhang H, Tan Y, Nie X, Zhou L, Liu Z, Ren Y, Yuan L, Zhang Y, Zhang J, Liang L, Chen X, Liu X, Wang P, Han X, Weng X, Chen Y, Yu T, Zhang X, Cai J, Chen R, Shi Z, Bian X.

Adherence of infusible biologics during the time of COVID-19 among patients with Inflammatory Bowel Disease: A nationwide VA cohort study

Khan N, Patel D, Xie D, Pernes T, Lewis J, Yang YX.

Could SARS-CoV-2-Induced Hyperinflammation Magnify the Severity of Coronavirus Disease (CoViD-19) Leading to Acute Respiratory Distress Syndrome?

Girija ASS, Shankar EM, Larsson M.

Lessons Learned to Date on COVID-19 Hyperinflammatory Syndrome: Considerations for Interventions to Mitigate SARS-CoV-2 Viral Infection and Detrimental Hyperinflammation

Cardone M, Yano M, Rosenberg AS, Puig M.

Novel Coronavirus-Induced NLRP3 Inflammasome Activation: A Potential Drug Target in the Treatment of COVID-19

Shah A.

Herpes zoster and severe acute herpetic neuralgia as a complication of COVID-19 infection

Shors AR.

Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy

Saini KS, Lanza C, Romano M, de Azambuja E, Cortes J, de Las Heras B, de Castro J, Lamba Saini M, Loibl S, Curigliano G, Twelves C, Leone M, Patnaik MM.

Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: Results from a single Italian Centre study on tocilizumab versus standard of care

Quartuccio L, Sonaglia A, McGonagle D, Fabris M, Peghin M, Pecori D, De Monte A, Bove T, Curcio F, Bassi F, De Vita S, Tascini C.

COVID-19: review on latest available drugs and therapies against SARS-CoV-2. Coagulation and inflammation cross-talking

Magro G.

COVID-19 Multisystem Inflammatory Syndrome in Three Teenagers with Confirmed SARS-CoV-2 Infection

Ng KF, Kothari T, Bandi S, Bird PW, Goyal K, Zoha M, Rai V, Tang JW.

Tocilizumab's efficacy in COVID-19 patients is determined by the presence of cytokine storm

Andrianopoulos I, Papathanasiou A, Papathanakos G, Chaidos A, Koulouras V.

COVID-19 and the endothelium

Jung F, Krüger-Genge A, Franke RP, Hufert F, Küpper JH.

A cross-sectional survey on the psychological impact of the COVID-19 pandemic on inflammatory bowel disease patients in Saudi Arabia

Mosli M, Alourfi M, Alamoudi A, Hashim A, Saadah O, Al Sulais E, AlAmeel T, Alharbi O, Bakari S, Meeralam Y, Alshobai S, Alsahafi M, Jawa H, Qari Y.

Nosocomial infections among patients with COVID-19, SARS and MERS: a rapid review and meta-analysis

Zhou Q, Gao Y, Wang X, Liu R, Du P, Wang X, Zhang X, Lu S, Wang Z, Shi Q, Li W, Ma Y, Luo X, Fukuoka T, Ahn HS, Lee MS, Liu E, Chen Y, Luo Z, Yang K; COVID-19 Evidence and Recommendations Working Group.

Emerging trends in COVID-19 treatment: learning from inflammatory conditions associated with cellular therapies

Cancio M, Ciccocioppo R, Rocco PRM, Levine BL, Bronte V, Bollard CM, Weiss D, Boelens JJ, Hanley PJ.

Inflammatory Bowel Disease in the COVID-19 Pandemic - the Patients' Perspective

Grunert PC, Reuken PA, Stallhofer J, Teich N, Stallmach A.

Surviving the storm: Dealing with COVID-19

Vandenbark AA, Meza-Romero R, Offner H.

Autoinflammatory and autoimmune conditions at the crossroad of COVID-19

Rodríguez Y, Novelli L, Rojas M, De Santis M, Acosta-Ampudia Y, Monsalve DM, Ramírez-Santana C, Costanzo A, Ridgway WM, Ansari AA, Gershwin ME, Selmi C, Anaya JM.

Serum Cytokine and Chemokine profile in Relation to the Severity of Coronavirus disease 2019 (COVID-19) in China

Chi Y, Ge Y, Wu B, Zhang W, Wu T, Wen T, Liu J, Guo X, Huang C, Jiao Y, Zhu F, Zhu B, Cui L.

Attenuated interferon and pro-inflammatory response in SARS-CoV-2-infected human dendritic cells is associated with viral antagonism of STAT1 phosphorylation

Yang D, Chu H, Hou Y, Chai Y, Shuai H, Lee AC, Zhang X, Wang Y, Hu B, Huang X, Yuen TT, Cai JP, Zhou J, Yuan S, Zhang AJ, Chan JF, Yuen KY.

A new pharmacological approach based on remdesivir aerosolized administration on SARS-CoV-2 pulmonary inflammation: A possible and rational therapeutic application

Contini C, Enrica Gallenga C, Neri G, Maritati M, Conti P.

Multi-modality imaging of inflammation and ischemia for assessment of myocardial injury in Covid-19

Yousefi-Koma A, Naghashzadeh F, Figtree GA, Patel S, Karimi Galougahi K.

COVID-19 revisiting inflammatory pathways of arthritis

Schett G, Manger B, Simon D, Caporali R.

Temporal profiling of plasma cytokines, chemokines and growth factors from mild, severe and fatal COVID-19 patients

Xu ZS, Shu T, Kang L, Wu D, Zhou X, Liao BW, Sun XL, Zhou X, Wang YY.

Could an Unrelated Live Attenuated Vaccine Serve as a Preventive Measure To Dampen Septic Inflammation Associated with COVID-19 Infection?

Fidel PL Jr, Noverr MC.

The perfect storm: COVID-19, mass incarceration and the opioid epidemic

Mukherjee TI, El-Bassel N.

"War to the knife" against thromboinflammation to protect endothelial function of COVID-19 patients

Guglielmetti G, Quaglia M, Sainaghi PP, Castello LM, Vaschetto R, Pirisi M, Corte FD, Avanzi GC, Stratta P, Cantaluppi V.

Therapeutic blockade of granulocyte macrophage colony-stimulating factor in COVID-19-associated hyperinflammation: challenges and opportunities

Mehta P, Porter JC, Manson JJ, Isaacs JD, Openshaw PJM, McInnes IB, Summers C, Chambers RC.

Rationale for targeting Complement in COVID-19

Polycarpou A, Howard M, Farrar CA, Greenlaw R, Fanelli G, Wallis R, Klavinskis LS, Sacks S.

Unraveling the mystery of Covid-19 Cytokine storm: From skin to organ systems

Garg S, Garg M, Prabhakar N, Malhotra P, Agarwal R.

A case series of COVID-19 patients with chronic hepatitis B virus infection

Li Y, Li C, Wang J, Zhu C, Zhu L, Ji F, Liu L, Xu T, Zhang B, Xue L, Yan X, Huang R, Wu C, Yan X.

Rationale for Evaluating PDE4 Inhibition for Mitigating against Severe Inflammation in COVID-19 Pneumonia and Beyond

Bridgewood C, Damiani G, Sharif K, Watad A, Bragazzi NL, Quartuccio L, Savic S, McGonagle D.

Management of patients with Hidradenitis Suppurativa during the COVID-19 pandemic

Montero-Vilchez T, Martinez-Lopez A, Salvador-Rodriguez L, Molina-Leyva A, Arias-Santiago S.

Targeting the interleukin-17 pathway to prevent acute respiratory distress syndrome associated with SARS-CoV-2 infection

Wiche Salinas TR, Zheng B, Routy JP, Ancuta P.

Catastrophic acute bilateral lower limbs necrosis associated with COVID-19 as a likely consequence of both vasculitis and coagulopathy

Del Giudice P, Boudoumi D, Le Guen B, Reverte M, Gutnecht J, Lacour JP, Kraemer JP, Motard A, Roa M.

Endothelial cell dysfunction: a major player in SARS-CoV-2 infection (COVID-19)?

Huertas A, Montani D, Savale L, Pichon J, Tu L, Parent F, Guignabert C, Humbert M.

Noradrenergic and serotonergic drugs may have opposing effects on COVID-19 cytokine storm and associated psychological effects

Fitzgerald PJ.

Protection against COVID-19 injury by qingfei paidu decoction via anti-viral, anti-inflammatory activity and metabolic programming

Chen J, Wang YK, Gao Y, Hu LS, Yang JW, Wang JR, Sun WJ, Liang ZQ, Cao YM, Cao YB.

Characteristics, Cardiac involvement, and Outcomes of Multisystem Inflammatory Disease of Childhood (MIS-C) Associated with SARS-CoV-2 Infection

Capone CA, Subramony A, Sweberg T, Schneider J, Shah S, Rubin L, Schleien C; Northwell Health COVID-19 Research Consortium, Epstein S, Johnson JC, Kessel A, Misra N, Mitchell E, Palumbo N, Rajan S, Rocker J, Williamson K, Davidson KW.

Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with SARS-CoV-2 Infection: A Multi-institutional Study from New York City

Kaushik S, Aydin SI, Derespina KR, Bansal PB, Kowalsky S, Trachtman R, Gillen JK, Perez MM, Soshnick SH, Conway EE Jr, Bercow A, Seiden HS, Pass RH, Ushay HM, Ofori-Amanfo G, Medar SS.

Impact of medication discontinuation on patients with inflammatory bowel disease during the COVID-19 outbreak

Chen J, Peng X, Zhang M, Zhi M.

Cautious Interpretation of Antiphospholipid Antibodies in COVID-19

Mehta S, Bhandari S, Mehta S.

Multisystem Inflammatory Syndrome in Children (MIS-C) with COVID-19: Insights from simultaneous familial Kawasaki Disease cases

Ebina-Shibuya R, Namkoong H, Shibuya Y, Horita N.

Tocilizumab treatment for Cytokine Release Syndrome in hospitalized COVID-19 patients: survival and clinical outcomes

Price CC, Altice FL, Shyr Y, Koff A, Pischel L, Goshua G, Azar MM, Mcmanus D, Chen SC, Gleeson SE, Britto CJ, Azmy V, Kaman K, Gaston DC, Davis M, Burrello T, Harris Z, Villanueva MS, Aoun-Barakat L, Kang I, Seropian S, Chupp G, Bucala R, Kaminski N, Lee AI, LoRusso PM, Topal JE, Dela Cruz C, Malinis M.

E-cigarette-induced pulmonary inflammation and dysregulated repair are mediated by nAChR α7 receptor: role of nAChR α7 in SARS-CoV-2 Covid-19 ACE2 receptor regulation

Wang Q, Sundar IK, Li D, Lucas JH, Muthumalage T, McDonough SR, Rahman I.

Acute encephalopathy with elevated CSF inflammatory markers as the initial presentation of COVID-19

Farhadian S, Glick LR, Vogels CBF, Thomas J, Chiarella J, Casanovas-Massana A, Zhou J, Odio C, Vijayakumar P, Geng B, Fournier J, Bermejo S, Fauver JR, Alpert T, Wyllie AL, Turcotte C, Steinle M, Paczkowski P, Dela Cruz C, Wilen C, Ko AI, MacKay S, Grubaugh ND, Spudich S, Barakat LA.

A rationale for blocking thromboinflammation in COVID-19 with Btk inhibitors

Nicolson PL, Welsh JD, Chauhan A, Thomas MR, Kahn ML, Watson SP.

Possible Old Drugs for Repositioning in COVID-19 Treatment: Combating Cytokine Storms from Haloperidol to Anti-interleukin Agents

Tulgar S, Ahıskalıoğlu A, Kök A, Thomas DT.

The position statement of the Polish Society of Gastroenterology and the Polish National Consultant in Gastroenterology regarding the management of patients with inflammatory bowel disease during the COVID-19 pandemic

Łodyga M, Eder P, Dobrowolska A, Reguła J, Rydzewska G.

Alpha-1 adrenergic receptor antagonists for preventing acute respiratory distress syndrome and death from cytokine storm syndrome

Vogelstein JT, Powell M, Koenecke A, Xiong R, Fischer N, Huq S, Khalafallah AM, Caffo B, Stuart EA, Papadopoulos N, Kinzler KW, Vogelstein B, Zhou S, Bettegowda C, Konig MF, Mensh B, Athey S.

COVID-19 Induced Hepatitis B Virus Reactivation: A Novel Case From the United Arab Emirates

Aldhaleei WA, Alnuaimi A, Bhagavathula AS.

Endotheliitis and Endothelial Dysfunction in Patients with COVID-19: Its Role in Thrombosis and Adverse Outcomes

Mosleh W, Chen K, Pfau SE, Vashist A.

A Putative Role of de-Mono-ADP-Ribosylation of STAT1 by the SARS-CoV-2 Nsp3 Protein in the Cytokine Storm Syndrome of COVID-19

Claverie JM.

COVID-19 hypothesis: Activated protein C for therapy of virus-induced pathologic thromboinflammation

Griffin JH, Lyden P.

Squalene-based multidrug nanoparticles for improved mitigation of uncontrolled inflammation in rodents

Dormont F, Brusini R, Cailleau C, Reynaud F, Peramo A, Gendron A, Mougin J, Gaudin F, Varna M, Couvreur P.

Off-label therapy targeting pathogenic inflammation in COVID-19

Romani L, Tomino C, Puccetti P, Garaci E.

"Acute" monoclonal gammopathy in severe COVID-19

Vazzana N, Ognibene S, Dipaola F.

The vascular endothelium: the cornerstone of organ dysfunction in severe SARS-CoV-2 infection

Pons S, Fodil S, Azoulay E, Zafrani L.

Strategies to Prevent SARS-CoV-2-Mediated Eosinophilic Disease in Association with COVID-19 Vaccination and Infection

Simon HU, Karaulov AV, Bachmann MF.

COVID-19 cytokine storm: The anger of inflammation

Mahmudpour M, Roozbeh J, Keshavarz M, Farrokhi S, Nabipour I.

Bacterial Pneumonia in COVID-19 critically ill patients: a case series

Dudoignon E, Caméléna F, Deniau B, Habay A, Coutrot M, Ressaire Q, Plaud B, Berçot B, Dépret F.

IL-6 combined with CD8+ T cell count early predict in-hospital mortality for patients with COVID-19

Luo M, Liu J, Jiang W, Yue S, Liu H, Wei S.

Herpes Zoster (shingles) complicating the course of COVID19 infection

Elsaie ML, Nada HA.

[Severe inflammation in children - cause for awareness during the current pandemic]

Horne A, Nordenhäll L.

[Effectiveness of the contingency plan of the internal inflammatory disease unit before Covid-19 infection.]

Carpio López D, Martínez Pillado M, Salgado Barreira Á, Daponte Angueira S, Díez Lage R, Castro Ortiz E, Fernández Salgado E, Pérez Galindo P, Turnes Vázquez J.

Revisiting the Protein C Pathway: An Opportunity for Adjunctive Intervention in COVID-19?

Mazzeffi M, Chow JH, Amoroso A, Tanaka K.

[Anti-cytokine therapy in novel coronavirus disease (COVID-19) – the first administration of tocilizumab in Hungary at a department of infectology]

Lakatos B, Gopcsa L, Gondos E, Riczu A, Várnai Z, Nagy É, Molnár E, Bekő G, Bobek I, Reményi P, Szlávik J, Sinkó J, Vályi-Nagy I.

Activated macrophages are the main inflammatory cell in COVID-19 interstitial pneumonia infiltrates. Is it possible to show their metabolic activity and thus the grade of inflammatory burden with (18)F-Fluorocholine PET/CT?

Savelli G, Bonacina M, Rizzo A, Zaniboni A.

Covid-19, Kawasaki disease, and Multisystem Inflammatory Syndrome in Children

Bassareo PP, Calcaterra G, Fanos V.

Lung under attack by COVID-19-induced cytokine storm: pathogenic mechanisms and therapeutic implications

Pelaia C, Tinello C, Vatrella A, De Sarro G, Pelaia G.

Factor VIII and Functional Protein C Activity in Critically Ill Patients With Coronavirus Disease 2019: A Case Series

Tabatabai A, Rabin J, Menaker J, Madathil R, Galvagno S, Menne A, Chow JH, Grazioli A, Herr D, Tanaka K, Scalea T, Mazzeffi M.

Potential for jaktinib hydrochloride to treat cytokine storms in patients with COVID-19

Meng X, Ling Y, Zhang L, Zhang Q, Dong P, Zhu T, Lu H.

Aspects of inflammatory bowel disease during the COVID-19 pandemic and general considerations

de León-Rendón JL, Hurtado-Salazar C, Yamamoto-Furusho JK.

Introductory histopathologic findings may shed light on COVID19 pediatric hyperinflammatory shock syndrome

Schnapp A, Abulhija H, Maly A, Armoni-Weiss G, Levin Y, Faitatziadou SM, Molho-Pessach V.

IL-6 Inhibitors in the Treatment of Serious COVID-19: A Promising Therapy?

Atal S, Fatima Z.

Combination of JAKinibs with Methotrexate or Anti-Cytokine Biologics in Patients with Severe COVID-19

Seif F, Pornour M, Mansouri D.

Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts

Wang J, Jiang M, Chen X, Montaner LJ.

COVID-19 & Periodontitis: The cytokine connection

Sahni V, Gupta S.

"Is really the cancer population at risk for more severe COVID-19? Some hints from the cytokine profile"

Gallo O, Giovanni LL, Orlando P, Martelli F, Piccica M, Lagi F, Trotta M.

Value of leukocytosis and elevated C-reactive protein in predicting severe coronavirus 2019 (COVID-19): A systematic review and meta-analysis

Yamada T, Wakabayashi M, Yamaji T, Chopra N, Mikami T, Miyashita H, Miyashita S.

Tuberculosis and type 2 Diabetes Mellitus: an inflammatory danger signal in the time of COVID-19

Wilkinson RJ.

Author Correction: Complement as a target in COVID-19?

Risitano AM, Mastellos DC, Huber-Lang M, Yancopoulou D, Garlanda C, Ciceri F, Lambris JD.

Bacterial and fungal infections among patients with SARS-CoV-2 pneumonia

Antinori S, Galimberti L, Milazzo L, Ridolfo AL.

Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases

Pablos JL, Abasolo L, Alvaro-Gracia JM, Blanco FJ, Blanco R, Castrejón I, Fernandez-Fernandez D, Fernandez-Gutierrez B, Galindo-Izquierdo M, Gonzalez-Gay MA, Manrique-Arija S, Mena Vázquez N, Mera Varela A, Retuerto M, Seijas-Lopez A.

Toxic shock-like syndrome and COVID-19: A case report of multisystem inflammatory syndrome in children (MIS-C)

Greene AG, Saleh M, Roseman E, Sinert R.

Effectiveness of corticoid pulses in patients with cytokine storm syndrome induced by SARS-CoV-2 infection

Callejas Rubio JL, Luna Del Castillo JD, de la Hera Fern√°ndez J, Guirao Arrabal E, Colmenero Ruiz M, Ortego Centeno N.

Chronic Inflammation in the Context of Everyday Life: Dietary Changes as Mitigating Factors

Margină D, Ungurianu A, Purdel C, Tsoukalas D, Sarandi E, Thanasoula M, Tekos F, Mesnage R, Kouretas D, Tsatsakis A.

Expression of SARS-CoV-2 Receptor ACE2 and Coincident Host Response Signature Varies by Asthma Inflammatory Phenotype

Camiolo MJ, Gauthier M, Kaminski N, Ray A, Wenzel SE.

Lactate dehydrogenase and C-reactive protein as predictors of respiratory failure in CoVID-19 patients

Erika P, Domenica Z, Paolo I, Luca R, Giulia L, Alessandro D, Marzia N, Giovanni Battista V, Donata G, Andrea V, Andrea M, Sergio B, Chiara T.

Cytokine Storm Induced by SARS-CoV-2

Song P, Li W, Xie J, Hou Y, You C.

Public health in the eye of the storm: what can we learn from the COVID-19 pandemic experience to strengthen public health services in Europe?

Azzopardi-Muscat N, Kluge HHP.

Rapid Review: Nonsteroidal Anti-inflammatory Agents and Aminosalicylates in COVID-19 Infections

Ehrenpreis ED, Kruchko DH.

Can steroids reverse the severe COVID-19 induced 'cytokine storm'?

Kolilekas L, Loverdos K, Giannakaki S, Vlassi L, Levounets A, Zervas E, Gaga M.

New (re)Purpose for an old drug: purinergic receptor blockade may extinguish the COVID-19 thrombo-inflammatory firestorm

Kanthi Y, Knight JS, Zuo Y, Pinsky DJ.

Inflammatory Bowel Disease and COVID-19-"Preventive" Sick Certificates as a Frequent Coping Strategy in the Face of the Pandemic

Schlabitz F, Teich N, Michl P, Walldorf J.

The possible pathophysiology mechanism of cytokine storm in elderly adults with COVID-19 infection: the contribution of "inflame-aging"

Meftahi GH, Jangravi Z, Sahraei H, Bahari Z.

May the Central Nervous System Be Fogged by the Cytokine Storm in COVID-19?: an Appraisal

Balcioglu YH, Yesilkaya UH, Gokcay H, Kirlioglu SS.

Paediatric Inflammatory Multisystem Syndrome: Temporally Associated with SARS-CoV-2 (PIMS-TS): Cardiac Features, Management and Short-Term Outcomes at a UK Tertiary Paediatric Hospital

Ramcharan T, Nolan O, Lai CY, Prabhu N, Krishnamurthy R, Richter AG, Jyothish D, Kanthimathinathan HK, Welch SB, Hackett S, Al-Abadi E, Scholefield BR, Chikermane A.

SARS-CoV-2 COVID-19 susceptibility and lung inflammatory storm by smoking and vaping

Kaur G, Lungarella G, Rahman I.

Kawasaki disease in a COVID-19-struck region

Stower H.

Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort

Pouletty M, Borocco C, Ouldali N, Caseris M, Basmaci R, Lachaume N, Bensaid P, Pichard S, Kouider H, Morelle G, Craiu I, Pondarre C, Deho A, Maroni A, Oualha M, Amoura Z, Haroche J, Chommeloux J, Bajolle F, Beyler C, Bonacorsi S, Carcelain G, Koné-Paut I, Bader-Meunier B, Faye A, Meinzer U, Galeotti C, Melki I.

COVID-19 and flu, a perfect storm

Belongia EA, Osterholm MT.

[Effect of Xuebijing injection on inflammatory markers and disease outcome of coronavirus disease 2019]

Wen L, Zhou Z, Jiang D, Huang K.

Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients

Convertino I, Tuccori M, Ferraro S, Valdiserra G, Cappello E, Focosi D, Blandizzi C.

Impaired Breakdown of Bradykinin and Its Metabolites as a Possible Cause for Pulmonary Edema in COVID-19 Infection

de Maat S, de Mast Q, Danser AHJ, van de Veerdonk FL, Maas C.

Interleukin-6 as prognosticator in patients with COVID-19: IL-6 and Covid-19

Grifoni E, Valoriani A, Cei F, Lamanna R, Gelli AMG, Ciambotti B, Vannucchi V, Moroni F, Pelagatti L, Tarquini R, Landini G, Vanni S, Masotti L.

Current status of mesenchymal stem cell therapy for immune/inflammatory lung disorders: Gleaning insights for possible use in COVID-19

Yen BL, Yen ML, Wang LT, Liu KJ, Sytwu HK.

Hypersegmented granulocytes and COVID-19 infection

Salib C, Teruya-Feldstein J.

Multi-System Inflammatory Syndrome in Children in Association with COVID-19

Simpson JM, Newburger JW.

Proinflammatory Cytokines in the Olfactory Mucosa Result in COVID-19 Induced Anosmia

Torabi A, Mohammadbagheri E, Akbari Dilmaghani N, Bayat AH, Fathi M, Vakili K, Alizadeh R, Rezaeimirghaed O, Hajiesmaeili M, Ramezani M, Simani L, Aliaghaei A.

SARS-CoV-2-related paediatric inflammatory multisystem syndrome, an epidemiological study, France, 1 March to 17 May 2020

Belot A, Antona D, Renolleau S, Javouhey E, Hentgen V, Angoulvant F, Delacourt C, Iriart X, Ovaert C, Bader-Meunier B, Kone-Paut I, Levy-Bruhl D.

Effectiveness of Tocilizumab in a COVID-19 Patient with Cytokine Release Syndrome

Uslu S.

D-dimer and C-reactive Protein Blood Levels Over Time Used to Predict Pulmonary Embolism in Two COVID-19 Patients

Becher Y, Goldman L, Schacham N, Gringauz I, Justo D.

Brief annotations on cytokine release syndrome and interleukin-6 therapeutic blockage in SARS-CoV-2/COVID-19

Amezcua-Guerra LM.

CNS inflammatory vasculopathy with antimyelin oligodendrocyte glycoprotein antibodies in COVID-19

Pinto AA, Carroll LS, Nar V, Varatharaj A, Galea I.

How nicotine can inhibit cytokine storm in the lungs and prevent or lessen the severity of COVID-19 infection?

Kloc M, Ghobrial RM, Kubiak JZ.

Covid-19 and inflammatory bowel disease: questions on incidence, severity, and impact of treatment?

Caron B, Arondel Y, Reimund JM.

Risk of Severe COVID-19 in Patients with Inflammatory Bowel Disease in United States. A Multicenter Research Network Study

Singh S, Khan A, Chowdhry M, Bilal M, Kochhar GS, Clarke K.

Clinical trials for inflammatory bowel disease: a global guidance during COVID-19 pandemic

Reinisch W, Danese S, Peyrin-Biroulet L, Loftus EV.

COVID-19 and pediatric inflammatory bowel disease: How to manage it?

Fragoso RP, Rodrigues M.

Immunometabolism: new insights and lessons from antigen-directed cellular immune responses

Ramalho R, Rao M, Zhang C, Agrati C, Ippolito G, Wang FS, Zumla A, Maeurer M.

The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation

La Rosée F, Bremer HC, Gehrke I, Kehr A, Hochhaus A, Birndt S, Fellhauer M, Henkes M, Kumle B, Russo SG, La Rosée P.

Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases

Dos Reis Neto ET, Kakehasi AM, de Medeiros Pinheiro M, Ferreira GA, Marques CDL, da Mota LMH, Dos Santos Paiva E, Pileggi GCS, Sato EI, Reis APMG, Xavier RM, Provenza JR.

Silibinin and SARS-CoV-2: Dual Targeting of Host Cytokine Storm and Virus Replication Machinery for Clinical Management of COVID-19 Patients

Bosch-Barrera J, Martin-Castillo B, Buxó M, Brunet J, Encinar JA, Menendez JA.

Azole-Resistant COVID-19-Associated Pulmonary Aspergillosis in an Immunocompetent Host: A Case Report

Meijer EFJ, Dofferhoff ASM, Hoiting O, Buil JB, Meis JF.

[The treatment of inflammatory bowel disease during the SARS-CoV-2 epidemic – practical advices: (A COVID–19-pandémia orvosszakmai kérdései)]

Resál T, Rutka M, Szántó K, Farkas K, Molnár T.

Cardiac MRI of Children with Multisystem Inflammatory Syndrome (MIS-C) Associated with COVID-19: Case Series

Blondiaux E, Parisot P, Redheuil A, Tzaroukian L, Levy Y, Sileo C, Schnuriger A, Lorrot M, Guedj R, Ducou le Pointe H.

Asian Pacific Association of Gastroenterology (APAGE) Inflammatory Bowel Disease (IBD) Working Party guidelines on IBD management during the COVID-19 pandemic

Ling KL, Hilmi I, Raja Ali RA, Leong RWL, Leung WK, Ng SC, Wu KC, Chen MH, Ran ZH, Hisamatsu T, Ahuja V, Makharia GK, Banerjee R, Wei SC, Wu DC, Pisespongsa P, Ye BD, Sollano J, Simadibrata M, Chuah SW, Ooi CJ.

A case of Bacillus cereus bacteremia in a COVID-19 patient treated with steroids

Osakwe N.

Rheumatologists and Pulmonologists at Temple University weather the COVID-19 storm together

Caricchio R, Criner GJ.

SARS-CoV-2 infection: The role of cytokines in COVID-19 disease

Costela-Ruiz VJ, Illescas-Montes R, Puerta-Puerta JM, Ruiz C, Melguizo-Rodríguez L.

C-reactive protein: a promising biomarker for poor prognosis in COVID-19 infection

Sahu BR, Kishor Kampa R, Padhi A, Panda AK.

Multisystem Inflammatory Syndrome Related to COVID-19 in Previously Healthy Children and Adolescents in New York City

Cheung EW, Zachariah P, Gorelik M, Boneparth A, Kernie SG, Orange JS, Milner JD.

COVID-19 Critical Illness Pathophysiology Driven by Diffuse Pulmonary Thrombi and Pulmonary Endothelial Dysfunction Responsive to Thrombolysis

Poor HD, Ventetuolo CE, Tolbert T, Chun G, Serrao G, Zeidman A, Dangayach NS, Olin J, Kohli-Seth R, Powell CA.

Reduced expression of COVID-19 host receptor, ACE2 is associated with small bowel inflammation, more severe disease, and response to anti-TNF therapy in Crohn's disease

Potdar AA, Dube S, Naito T, Botwin G, Haritunians T, Li D, Yang S, Bilsborough J, Denson LA, Daly M, Targan SR, Fleshner P, Braun J, Kugathasan S, Stappenbeck TS, McGovern DPB.

An inflammatory cytokine signature helps predict COVID-19 severity and death

Del Valle DM, Kim-Schulze S, Hsin-Hui H, Beckmann ND, Nirenberg S, Wang B, Lavin Y, Swartz T, Madduri D, Stock A, Marron T, Xie H, Patel MK, van Oekelen O, Rahman A, Kovatch P, Aberg J, Schadt E, Jagannath S, Mazumdar M, Charney A, Firpo-Betancourt A, Mendu DR, Jhang J, Reich D, Sigel K, Cordon-Cardo C, Feldmann M, Parekh S, Merad M, Gnjatic S.

Erythrocytes Reveal Complement Activation in Patients with COVID-19

Lam LM, Murphy SJ, Kuri-Cervantes L, Weisman AR, Ittner CAG, Reilly JP, Pampena MB, Betts MR, Wherry EJ, Song WC, Lambris JD, Cines DB, Meyer NJ, Mangalmurti NS.

Cross-sectional IgM and IgG profiles in SARS-CoV-2 infection

Ozturk T, Howell C, Benameur K, Ramonell RP, Cashman K, Pirmohammed S, Bassit L, Roback J, Marconi VC, Schinazi RF, Wharton W, Lee FE, Hu WT.

A systematic review of antibody mediated immunity to coronaviruses: antibody kinetics, correlates of protection, and association of antibody responses with severity of disease

Huang AT, Garcia-Carreras B, Hitchings MDT, Yang B, Katzelnick LC, Rattigan SM, Borgert BA, Moreno CA, Solomon BD, Rodriguez-Barraquer I, Lessler J, Salje H, Burke D, Wesolowski A, Cummings DAT.

Type 2 and interferon inflammation strongly regulate SARS-CoV-2 related gene expression in the airway epithelium

Sajuthi SP, DeFord P, Jackson ND, Montgomery MT, Everman JL, Rios CL, Pruesse E, Nolin JD, Plender EG, Wechsler ME, Mak AC, Eng C, Salazar S, Medina V, Wohlford EM, Huntsman S, Nickerson DA, Germer S, Zody MC, Abecasis G, Kang HM, Rice KM, Kumar R, Oh S, Rodriguez-Santana J, Burchard EG, Seibold MA.

COVID-19: hemoglobin, iron, and hypoxia beyond inflammation. A narrative review

Cavezzi A, Troiani E, Corrao S.

Defining Association between COVID-19 and the Multisystem Inflammatory Syndrome in Children through the Pandemic

Kim YJ, Park H, Choi YY, Kim YK, Yoon Y, Kim KR, Choi EH.

Hyperacute multi-organ thromboembolic storm in COVID-19: a case report

Chibane S, Gibeau G, Poulin F, Tessier P, Goulet M, Carrier M, Lanthier S.

Ursodeoxycholic acid as a candidate therapeutic to alleviate and/or prevent COVID-19-associated cytokine storm

Abdulrab S, Al-Maweri S, Halboub E.